Search Results

LDN Q&A: Your Questions Answered A Supportive Guide for the LDN Support Group Download your free LDN Primer Booklet from www.LDNSupportGroup.org January 18 2026 Important Disclaimer This guide shares information based on published research and community experiences. It is not medical advice. LDN is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Always consult your doctor before starting, adjusting, or stopping any medication. Part 1: Quick FAQ These are the most common questions we see in our community. For deeper explanations, see the comprehensive guide in Part 2. Q1: Should I take LDN in the morning or at night? There's no universal "right" answer. Nighttime is traditionally recommended, but if you experience insomnia, morning dosing may work better for you. Some people feel drowsy taking it in the morning initially, but this often improves. Try what feels right and give any change at least 1-2 weeks. Q2: I'm having terrible insomnia on LDN. What should I do? Insomnia is one of the most common side effects, especially at night. Options include: switching to morning dosing, reducing your dose, or if you just started, giving it 1-2 weeks to see if it improves. If insomnia persists despite these adjustments, discuss with your prescriber. Q3: Should I push through side effects or reduce my dose? It depends on severity. Mild effects (slight sleep changes, vivid dreams) often resolve in 1-2 weeks. Moderate to severe effects (significant insomnia, bad headaches, vertigo, irritability) are signals to reduce your dose. If symptoms are getting worse rather than better, back off. Q4: I tolerated LDN fine at first, but now I'm getting worse the longer I take it. Why? This pattern happens to some people. LDN's effects can be cumulative, and what your body tolerated initially may become too much over time. Your underlying condition may also have changed. If you've tried reducing doses and breaks without success, discuss with your provider whether to stop. Q5: How slowly should I increase my dose? Standard protocols suggest reaching 4.5 mg in 2-4 weeks, but this is too fast for many people. If you're sensitive or severely ill, consider 2-4 week intervals between increases—or even longer. Some very sensitive patients need months between dose changes. Patience is key. Q6: What's the lowest dose I can try? Clinical protocols recognize ultra-low doses in the microgram range (1-2 mcg), very-low doses (0.01-0.5 mg), and traditional low doses (1-4.5 mg). If you're highly sensitive, starting at 0.5 mg or lower and titrating very slowly may help. Discuss options with your prescriber. Q7: Does it matter which compounding pharmacy I use? Some people report differences between pharmacies. If you're sensitive, you might try a formulation without silica or other common fillers. There isn't definitive research on this, but some individuals with MCAS or sensitivities notice improvements with cleaner formulations. Q8: Is it normal to feel worse before feeling better? Some people experience a brief adjustment period with mild side effects that resolve. However, feeling significantly worse that doesn't improve over 2-4 weeks isn't necessarily "normal"—it may mean the dose is too high for you. Listen to your body. Q9: What if LDN just doesn't work for me? Research suggests about one-third of people don't respond to standard LDN therapy. This isn't a personal failure—it may mean your condition works through different pathways, or your endorphin reserves are depleted. Some people try again successfully later after addressing other health factors. Q10: I have POTS, hEDS, or MCAS. Any special considerations? These complex conditions often require extra care. Start at very low doses and titrate extremely slowly. For MCAS, LDN alone may not be sufficient—complementary treatments like mast cell stabilizers are sometimes added. Work closely with a provider experienced in these conditions. Part 2: Comprehensive Guide This section provides in-depth information based on clinical experience and published research. Remember, everyone's journey with LDN is unique. Understanding How People Respond to LDN One of the most important things to understand is that not everyone responds to LDN in the same way . Clinical experience and research suggest that people generally fall into three categories: Category 1: LDN Works Well on Its Own For some people, LDN alone produces meaningful and sustained improvement. These individuals typically have adequate baseline endorphin reserves, moderate symptom severity, and good overall functional capacity. Research in fibromyalgia has shown response rates around 57-65%, with some studies demonstrating significant pain reduction compared to placebo (Younger et al., 2013; Toljan & Vrooman, 2023). Category 2: LDN Helps, But Isn't Enough Alone In more complex situations, LDN plays an important supporting role but may not achieve the full results someone is hoping for on its own. Conditions that often fall into this category include mast cell activation syndrome (MCAS), Long COVID, chronic inflammatory response syndrome (CIRS), and complex regional pain syndrome. In these cases, LDN may calm the immune system enough to make other treatments more effective and better tolerated (Kim, 2025). Category 3: Non-Responders Some people simply don't respond to LDN at any dose. This may relate to severely depleted endorphin reserves, genetic variations in opioid receptor function, or conditions that aren't primarily mediated by the pathways LDN affects. If you've given LDN a thorough trial without benefit, this doesn't mean you've failed—it may simply mean LDN isn't the right tool for your particular situation. The Endorphin Reserve Concept A key concept in understanding LDN therapy is what clinicians call "endorphin reserve." LDN works partly by temporarily blocking opioid receptors, which triggers your body to produce more endorphins. But if your body's endorphin-producing capacity is already depleted from prolonged illness, this mechanism may not work as expected. Healthcare providers experienced with LDN often assess functional capacity to estimate endorphin reserve. They may ask about duration of illness, sleep quality, energy levels, recovery time from setbacks, and ability to perform daily activities. People with very low functional capacity often need a much gentler approach to starting LDN (Kim, 2025). Dosing Strategies: One Size Does NOT Fit All This is perhaps the most important section for our community members who are struggling with side effects. Standard Dosing The commonly cited protocol of starting at 1.5 mg and working up to 4.5 mg over 2-4 weeks works well for people with moderate illness and good functional capacity. However, many people in health support communities like ours have more complex situations that require a different approach. Low and Ultra-Low Dosing The LDN Research Trust recognizes three dosing categories: ultra-low dose (microgram range, 1-2 mcg), very-low dose (0.01-0.5 mg daily), and the traditional low dose (1-4.5 mg, sometimes up to 10 mg). At very low doses, naltrexone may work through different mechanisms, potentially acting more gently on the system through a phenomenon called hormesis (LDN Research Trust, 2024). For people who are severely ill, have low functional capacity, or are highly sensitive, starting at 0.5 mg or even lower and increasing very slowly may be essential. Some sensitive individuals may need 2-4 weeks between dose increases, while the most sensitive may need 1-3 months between adjustments. This is a marathon, not a sprint. When Side Effects Persist at Low Doses If you're experiencing persistent side effects even at very low doses, this may indicate that your endorphin reserves are significantly depleted. Options include dropping to an even lower dose, extending the time between dose increases, or discussing with your healthcare provider whether LDN is appropriate for your current situation. Sometimes stepping away and addressing other aspects of health first allows people to try LDN again successfully later. Morning vs. Night: Finding What Works for You The timing question comes up constantly in our group, and for good reason—it can make a significant difference in tolerability. Nighttime dosing  is traditionally recommended because LDN's brief opioid receptor blockade coincides with the body's natural endorphin release during sleep. Many people do well with this approach. However, insomnia and vivid dreams  are among the most commonly reported side effects, and taking LDN at night can make these worse for some people. Morning dosing  works better for those who experience sleep disruption. Some people report feeling drowsy or "out of it" when first switching to morning dosing, but this often improves as the body adjusts. There's no definitive research saying one time is universally better—it's about finding what works for your body. If nighttime dosing is causing severe insomnia, switching to morning is absolutely worth trying. Give any timing change at least a week or two before deciding if it's working. Common Side Effects and What They May Mean Side Effect What It May Indicate Suggested Approach Insomnia / vivid dreams Common with nighttime dosing Try morning dosing; may improve with time Headaches Adjustment period or dose too high Often resolves in 1-2 weeks; reduce dose if severe Fatigue / drowsiness Body adjusting; may indicate dose sensitivity Consider timing change; reduce dose if persistent Irritability / mood changes Possible dose sensitivity Reduce dose; ensure adequate rest Nausea / GI upset Common early effect Take with food; usually improves Vertigo / dizziness May indicate dose too high Reduce dose; titrate more slowly Increased pain (temporary) Some experience initial flare May resolve; discuss with provider if persists Most side effects are temporary and resolve within the first few weeks. However, if side effects persist or worsen despite dose adjustments, this is important information to share with your healthcare provider. When You Initially Tolerated LDN But Now Can't This is a pattern we see repeatedly in our community, and it can be deeply frustrating. You started LDN without problems, built up to a certain dose, and then symptoms appeared that get worse the longer you stay on it—even when you drop back down. Several things may explain this pattern. First, LDN's effects are cumulative over time, so what your body tolerated at first may become too much as levels build. Second, your underlying condition may have changed, affecting how you respond to LDN. Third, there may be interactions with other factors in your health that weren't present initially. If you've tried reducing the dose, taking breaks, and using the every-other-day method without success, it may be time to have a candid conversation with your prescriber about whether to discontinue—at least for now. Stopping LDN is not a failure. Some people return to it successfully later when other aspects of their health have been addressed. Should I Power Through Side Effects or Reduce My Dose? This is one of the most common questions we receive, and the answer depends on the severity and type of side effects. Mild, tolerable side effects  (slight sleep changes, mild headache, vivid but not disturbing dreams) often resolve within 1-2 weeks as your body adjusts. If the side effects aren't significantly impacting your quality of life, it may be reasonable to stay at your current dose and give it more time. Moderate to severe side effects  (significant insomnia, severe headaches, marked irritability, vertigo, blurred vision) are signals from your body that the current dose is too much. In these cases, reducing the dose or pausing is generally the wiser choice. There's no benefit to "pushing through" if it means feeling miserable. A practical approach: if side effects are getting progressively worse rather than improving, back off. If they're stable or slowly improving, you might give it more time. Special Considerations for POTS, hEDS, and MCAS Many members of our community are managing complex overlapping conditions like postural orthostatic tachycardia syndrome (POTS), hypermobile Ehlers-Danlos syndrome (hEDS), and mast cell activation syndrome (MCAS). These conditions often require extra care when starting LDN. For MCAS in particular, LDN may be helpful but often isn't sufficient on its own. Clinical protocols sometimes combine LDN with mast cell stabilizers like ketotifen or cromolyn sodium (Weinstock et al., 2018). If you have MCAS and are struggling with LDN tolerance, discussing these complementary approaches with your healthcare provider may be worthwhile. People with these conditions often benefit from starting at the lowest possible doses and titrating extremely slowly—sometimes over many months rather than weeks. Does the Compounding Formulation Matter? Some community members report significant differences in how they tolerate LDN from different compounding pharmacies or with different inactive ingredients (excipients). While there isn't robust research on this topic, clinical experience suggests that some people are sensitive to fillers like silica, certain dyes, or other additives. If you're highly sensitive or have MCAS, working with a compounding pharmacy that can prepare LDN with minimal excipients may be worth exploring. Common requests include formulations without silica, dye-free preparations, and hypoallergenic fillers. When to Consider Stopping LDN LDN isn't right for everyone, and recognizing when it's not working is just as important as giving it a fair trial. Consider discussing discontinuation with your healthcare provider if: side effects persist despite multiple dose adjustments and timing changes, you've tried for several months without any perceived benefit, side effects significantly outweigh any benefits, or your symptoms are progressively worsening on the medication. Stopping LDN is generally straightforward since it doesn't cause physical dependence. Some people notice temporary changes when stopping, but these typically resolve within a few days. A Final Word of Support Managing chronic health conditions is challenging, and trying to optimize LDN therapy can feel like solving a puzzle with many pieces. Please remember that your experience is valid, even if it doesn't match what others describe. What works beautifully for one person may not work for another, and that's okay. Always work with a healthcare provider who understands LDN and can help guide your decisions. This community is here to share experiences and support each other, but personalized medical guidance is essential. Be patient with yourself. Be willing to adjust. And know that whether LDN ends up being part of your health toolkit or not, you're on a path toward understanding your body better. LDN Support Group About the Author: Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in using LDN (Low Dose Naltrexone) to treat autoimmune conditions, chronic pain, integrative oncology, and complex conditions, including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com   Clinical:   www.directintegrativecare.com This document is for educational purposes only and does not constitute medical advice. Individual results vary. Please consult your healthcare provider for personalized guidance. References Bruun, K. D., Christensen, R., Amris, K., et al. (2021). Low-dose naltrexone for the treatment of fibromyalgia: Protocol for a double-blind, randomized, placebo-controlled trial. Trials, 22(1), 804. https://doi.org/10.1186/s13063-021-05804-6 Kim, Y. H. (2018). Ultra low dose naltrexone, micro dosing [Conference presentation]. LDN Research Trust 2018 Conference. Kim, Y. H. (2025). Low-dose naltrexone primer: A clinical guide to optimizing LDN therapy. Direct Integrative Care. https://www.directintegrativecare.com LDN Research Trust. (2024). Dosing information for prescribers. https://ldnresearchtrust.org Toljan, K., & Vrooman, B. (2023). Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions. Biomedicines, 11(4), 1087. https://doi.org/10.3390/biomedicines11041087 Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, bcr2017221405. https://doi.org/10.1136/bcr-2017-221405 Yang, J., Shin, K. M., Do, A., et al. (2023). The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: A systematic review. Journal of Pain Research, 16, 1017-1023. https://doi.org/10.2147/JPR.S397456 Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial. Arthritis & Rheumatism, 65(2), 529-538. https://doi.org/10.1002/art.37734 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451-459. https://doi.org/10.1007/s10067-014-2517-2

Yoon Hang Kim, MD, MPH Abstract Most patients assume that if something is sold at a health food store or online as a "supplement," it must be safe. After more than two decades in integrative medicine, I can tell you this assumption gets people into trouble every week. This review covers the supplements I see most commonly abused in clinical practice—stimulants marketed for weight loss, GABAergic substances like phenibut that cause rapid dependence, and kratom with its opioid-like effects. My goal is to give fellow clinicians practical knowledge to identify these patterns and have honest conversations with patients about the real risks involved. Keywords: dietary supplements, substance abuse, kratom, phenibut, tianeptine, stimulants, GHB Introduction The supplement industry in North America has grown into a $40 billion market (Mordor Intelligence, 2025), and with that growth has come a troubling increase in abuse and misuse. Poison control centers are seeing more supplement-related calls every year, affecting everyone from teenagers to seniors (Rao et al., 2017). What strikes me most is how often patients are genuinely surprised to learn that something they bought legally could cause serious harm. Let me clarify the terminology I'll use throughout this review. "Abuse" means someone is taking a supplement specifically to get high or achieve a psychotropic effect. "Misuse" is broader—it includes taking something for purposes other than its intended use, like using laxatives for weight loss (Smith et al., 2013). Both patterns can lead to serious consequences, and both are more common than many clinicians realize (Biggs et al., 2017). The Weight Loss and Performance Crowd: Stimulants I'll start with stimulants because these are the ones that land people in the emergency room with chest pain and palpitations. The patients are often young, healthy, and completely blindsided that their pre-workout supplement could cause a cardiac event. DMAA (1,3-Dimethylamylamine). This one has been officially illegal since 2013, yet I still see it showing up in supplements people order online. The FDA banned it after reports of cardiac arrests and deaths in young, otherwise healthy adults—including active-duty soldiers (Eliason et al., 2012). Manufacturers used to claim DMAA came from geranium plants, but laboratory testing never confirmed that; it's a synthetic stimulant, plain and simple (Health Canada, 2011; Archer et al., 2015). If a patient mentions they're using a pre-workout that gives them an unusually intense buzz, it's worth checking the ingredient list carefully. Bitter Orange. When ephedra was banned in 2004, the supplement industry pivoted to bitter orange as an "ephedra-free" alternative. Here's what they didn't advertise: bitter orange contains synephrine and octopamine, which are structurally similar to the catecholamines your body makes naturally (Pawar et al., 2020). Combined with caffeine—which most of these products also contain—you're looking at real cardiovascular risk. I've seen patients present with hypertensive urgency after using these products for just a few weeks. The myocardial infarctions and strokes reported in the literature aren't theoretical; they happen (TRC Healthcare, n.d.). Concentrated Caffeine. Most people don't think of caffeine as dangerous, and in moderate doses from coffee or tea, it isn't. But the concentrated powders and liquids sold online are a different story entirely. Here's a number that gets patients' attention: one teaspoon of pure caffeine powder contains roughly the same amount of caffeine as 32 cups of coffee (Temple et al., 2017). The lethal dose is somewhere between 10 and 14 grams—not hard to reach accidentally with a powder. The FDA restricted bulk sales in 2018 after deaths, but these products still circulate (FDA, 2018). Whenever a patient tells me they're taking caffeine powder for energy or workouts, I make sure they understand the math. Ephedra. Even though ephedra has been banned for over 20 years, I still encounter patients who've ordered it online. The historical data is striking: before the ban, ephedra accounted for less than 1% of herbal supplement sales but was responsible for 64% of adverse reaction reports to poison control centers (Lai et al., 2021). That disproportion tells you everything. What makes ephedra particularly dangerous is that serious events—cardiac arrhythmias, strokes, sudden death—can occur even at low doses with short-term use (NCCIH, n.d.). There's no "safe" way to use it recreationally. Laxatives: The Hidden Pattern Laxative abuse often flies under the radar because the products are so mundane. Senna, castor oil—these are things your grandmother probably had in her medicine cabinet. But chronic misuse, particularly for weight control, can cause significant electrolyte disturbances. Hypokalemia is the main concern; severe potassium depletion can cause dangerous arrhythmias (TRC Healthcare, n.d.). The good news is that the old fears about permanent "cathartic colon" have been largely disproven by better research (Müller-Lissner et al., 2005). The bad news is that the pattern often indicates an underlying eating disorder that needs attention beyond just stopping the laxatives. The Recreational Users: GABAergic Substances These are the supplements that worry me most, because the patients using them often have no idea how quickly physical dependence develops—or how dangerous withdrawal can be. GHB (Gamma-Hydroxybutyrate). GHB exists naturally in the brain in tiny amounts (Tunnicliff, 1992), which some people use to justify its safety. Don't believe it. The doses used recreationally are orders of magnitude higher than physiological levels, and the margin between a "recreational" dose and a dangerous one is razor-thin. GHB's euphoric effects made it popular at clubs and raves, and it remains tragically associated with drug-facilitated sexual assault. What really concerns me clinically is the withdrawal syndrome: patients can develop severe delirium with hallucinations and seizures that require ICU-level care (TRC Healthcare, n.d.). If someone has been using GHB regularly, they need medical supervision to stop. Phenibut. This is the one I've been seeing more frequently in the past few years. Phenibut is a GABA analog developed in Russia decades ago for anxiety (Lapin, 2001). It was never approved in the United States, but that hasn't stopped it from being sold openly online as a "supplement" or "nootropic" (Cohen et al., 2022). The FDA has warned companies to stop, but enforcement is limited. Here's what patients need to understand: dependence can develop in days, not weeks. I've had patients tell me they took phenibut for "just a week" and then experienced seizures when they stopped (Graves et al., 2020). This is not a mild substance. Tianeptine. If you haven't encountered tianeptine yet, you probably will soon. It's sold at gas stations and convenience stores under brand names like "Tianna" and "Zaza," marketed for mood and energy. What it actually is: an atypical antidepressant that activates opioid receptors at higher doses (Edinoff et al., 2023). People are using it to get high, and some are using it to self-treat opioid withdrawal—trading one dependence for another. Making matters worse, recent testing has found some tianeptine products adulterated with synthetic cannabinoids (Counts et al., 2025). Several states have started scheduling it after seeing fatalities and emergency department visits spike (Hershey et al., 2024). The Opioid Alternative: Kratom Kratom occupies a complicated space in integrative medicine. Some patients swear by it for chronic pain; others have developed serious dependence. I try to approach it with nuance rather than reflexive dismissal, but the facts need to be laid out clearly. Kratom comes from a Southeast Asian tree, and its effects depend heavily on dose. Lower doses (1-5 grams) produce stimulation; higher doses (5-15 grams) produce opioid-like analgesia and sedation (TRC Healthcare, n.d.). This isn't metaphorical—the active alkaloids, particularly 7-hydroxymitragynine, directly activate mu-opioid receptors. In fact, 7-hydroxymitragynine is estimated to be about 10 times more potent than morphine (Griffin & Webb, 2018). That's not a comparison I make lightly. Poison control data show a sharp increase in kratom exposures between 2014 and 2019, with older adults showing particularly severe outcomes (Graves et al., 2021). There have also been quality control disasters: a 2018 Salmonella outbreak sickened 134 people across 35 states (CDC, 2018), and lab testing has found some products intentionally spiked with higher concentrations of the most potent alkaloids (Lydecker et al., 2016). When patients ask me about kratom, I don't tell them it's evil. I tell them it's an opioid-receptor agonist with no quality control, no standardized dosing, and real dependence potential. If they're using it to manage pain, we need to talk about why—and what safer alternatives might exist. Commonly Abused Dietary Supplements: A Clinical Review Practical Takeaways for Clinicians Ask about supplements explicitly. I've learned to phrase it broadly: "Are you taking anything you buy at a health food store, online, or at a gas station—vitamins, herbs, energy products, anything like that?" The gas station question usually prompts a pause and sometimes a confession about tianeptine or kratom. Watch for red flags in the history. Someone buying laxatives frequently may have an eating disorder. Someone with unexplained tachycardia may be using stimulant supplements they haven't mentioned. Someone in apparent opioid withdrawal who denies opioid use may be coming off kratom. Know your drug interactions. Stimulant supplements combined with prescription stimulants or MAOIs can cause hypertensive crisis. GABAergic supplements combined with benzodiazepines or alcohol can cause respiratory depression. Kratom can trigger false-positive drug screens and interact with medications metabolized by cytochrome P450 enzymes. Some stimulants can also cause false-positive amphetamine results (Levisky et al., 2003). Don't try to detox phenibut or GHB in the outpatient setting. These patients need medical supervision. The withdrawal syndromes can include seizures, and they can be life-threatening. Closing Thoughts The "natural equals safe" myth is probably the single most dangerous misconception I encounter in practice. Arsenic is natural. Hemlock is natural. Natural says nothing about safety. What matters is dose, quality, and mechanism—and for many of the supplements covered in this review, all three are problematic. As integrative medicine practitioners, we're in a unique position. Patients come to us because they're interested in alternatives to conventional medicine. That gives us both the opportunity and the responsibility to help them distinguish between supplements that might genuinely help and those that could cause real harm. We can't do that if we're reflexively dismissive of all supplements—but we also can't do it if we're unwilling to have frank conversations about the ones that pose serious risks. My hope is that this review gives you some practical tools for those conversations. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com References Archer, J. R., Dargan, P. I., Lostia, A. M., van der Walt, J., Henderson, K., Drake, N., Sharma, S., Wood, D. M., & Huggett, D. B. (2015). Running an unknown risk: A marathon death associated with the use of 1,3-dimethylamylamine (DMAA). Drug Testing and Analysis, 7 (5), 433-438. Biggs, J. M., Morgan, J. A., Lardieri, A. B., Kishk, O. A., & Klein-Schwartz, W. (2017). Abuse and misuse of selected dietary supplements among adolescents: A look at poison center data. Journal of Pediatric Pharmacology and Therapeutics, 22 (6), 385-393. Centers for Disease Control and Prevention. (2018). Multistate outbreak of Salmonella infections linked to kratom. https://www.cdc.gov/salmonella/kratom-02-18/index.html Cohen, P. A., Ellison, R. R., Travis, J. C., Gaufberg, S. V., & Gerona, R. (2022). Quantity of phenibut in dietary supplements before and after FDA warnings. Clinical Toxicology, 60 (4), 486-488. Counts, C., Spadaro, A., Cerbini, T., Patel, K., Calello, D. P., & Marcus, S. M. (2025). An outbreak of synthetic cannabinoid-adulterated tianeptine products in New Jersey: Case series. Journal of Medical Toxicology, 21 , 253-259. Edinoff, A. N., Sall, S., Beckman, S. P., Hegefeld, T. L., Kaye, A. M., & Kaye, A. D. (2023). Tianeptine, an antidepressant with opioid agonist effects: Pharmacology and abuse potential, a narrative review. Pain and Therapy, 12 (5), 1121-1134. Eliason, M. J., Eichner, A., Cancio, A., Bestervelt, L., Adams, B. D., & Deuster, P. A. (2012). Case reports: Death of active duty soldiers following ingestion of dietary supplements containing 1,3-dimethylamylamine (DMAA). Military Medicine, 177 (12), 1455-1459. Graves, J. M., Dilley, J., & Kubsad, S. (2020). Notes from the field: Phenibut exposures reported to poison centers—United States, 2009-2019. Morbidity and Mortality Weekly Report, 69 (35), 1227-1228. Graves, J. M., Dilley, J. A., Terpak, L., Brooks-Russell, A., Whitehill, J. M., Liebelt, E. L., & Spiller, H. A. (2021). Kratom exposures among older adults reported to U.S. poison centers, 2014-2019. Journal of the American Geriatrics Society, 69 (8), 2176-2184. Griffin, O. H., & Webb, M. E. (2018). The scheduling of kratom and selective use of data. Journal of Psychoactive Drugs, 50 (2), 114-120. Health Canada. (2011). Classification of 1,3-dimethylamylamine (DMAA) . Government of Canada. Hershey, H. L., Onyango, E. M., Durst, K., Harbin, E., Harris, T. R., & Chen, P. Y. (2024). Tianeptine-involved emergency department visits, fatal overdoses, and substance seizures in Tennessee, 2021-2023. Drug and Alcohol Dependence Reports, 12 , 100272. Lai, S., Yu, C., Dennehy, C. E., Tsourounis, C., & Lee, K. P. (2021). Online marketing of ephedra weight loss supplements: Labeling and marketing compliance with the U.S. Food and Drug Administration ban on ephedra. Journal of Alternative and Complementary Medicine, 27 (9), 796-802. Lapin, I. (2001). Phenibut (beta-phenyl-GABA): A tranquilizer and nootropic drug. CNS Drug Reviews, 7 (4), 471-481. Levisky, J. A., Karch, S. B., Bowerman, D. L., Jenkins, W. W., Johnson, D. G., Davies, D., & Barker, L. (2003). False-positive RIA for methamphetamine following ingestion of an Ephedra-derived herbal product. Journal of Analytical Toxicology, 27 (2), 123-124. Lydecker, A. G., Sharma, A., McCurdy, C. R., Avery, B. A., Babu, K. M., & Boyer, E. W. (2016). Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. Journal of Medical Toxicology, 12 (4), 341-349. Mordor Intelligence. (2025). North America dietary supplement market—Growth, trends, and forecast (2025-2030) . https://www.mordorintelligence.com/industry-reports/north-america-dietary-supplement-market Müller-Lissner, S. A., Kamm, M. A., Scarpignato, C., & Wald, A. (2005). Myths and misconceptions about chronic constipation. American Journal of Gastroenterology, 100 (1), 232-242. National Center for Complementary and Integrative Health. (n.d.). Ephedra . https://www.nccih.nih.gov/health/ephedra Pawar, R. S., Sagi, S., & Leontyev, D. (2020). Analysis of bitter orange dietary supplements for natural and synthetic phenethylamines by LC-MS/MS. Drug Testing and Analysis, 12 (9), 1241-1251. Rao, N., Spiller, H. A., Michaels, N. L., Casavant, M. J., & Chounthirath, T. (2017). An increase in dietary supplement exposures reported to U.S. poison control centers. Journal of Medical Toxicology, 13 (3), 227-237. Smith, S. M., Dart, R. C., Katz, N. P., et al. (2013). Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain, 154 (11), 2287-2296. Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017). The safety of ingested caffeine: A comprehensive review. Frontiers in Psychiatry, 8 , 80. TRC Healthcare. (n.d.). Natural Medicines Database [Monographs for Bitter Orange, Senna, GHB, and Kratom]. https://naturalmedicines.therapeuticresearch.com Tunnicliff, G. (1992). Significance of gamma-hydroxybutyric acid in the brain. General Pharmacology, 23 (6), 1027-1034. U.S. Food and Drug Administration. (2018). FDA takes step to protect consumers against dietary supplements containing dangerously high levels of extremely concentrated or pure caffeine. https://www.fda.gov/news-events/press-announcements

Key Takeaways Medicinal mushrooms like reishi, shiitake, lion’s mane, cordyceps, chaga, turkey tail, and maitake have been used in traditional chinese medicine and other healing systems for over 2,000 years. Modern research is now validating their potential for immune support, metabolic health, brain function, and adjunctive cancer care. The strongest current evidence supports medicinal mushroom use for immune modulation, quality of life improvements alongside cancer therapy, blood sugar and cholesterol management, and cognitive support. These fungi work as complementary therapies, not stand-alone cures, and should be integrated with conventional medicine. Key bioactive compounds driving these effects include β-glucans, terpenoids, phenolics, and fungal proteins. These compounds have been tested extensively in cell and animal studies, with human clinical trials dating back to the 1970s when lentinan was approved in Japan as a cancer adjuvant. Supplement quality varies dramatically across the market. Extracts derived from the fruiting body with standardized β-glucan content are generally preferable to unstandardized mycelium-on-grain products, which may contain significant amounts of residual starch. More large, controlled human trials are needed to fully establish therapeutic protocols. However, current data justify cautious, informed use under guidance from healthcare professionals, particularly for individuals with chronic diseases or those taking medications that might interact with mushroom compounds. Introduction to Medicinal Mushrooms The use of edible and medicinal mushrooms stretches back more than two millennia across multiple healing traditions. In traditional chinese medicine, Japanese Kampo, and Korean folk medicine, species like Ganoderma lucidum (reishi) and Lentinula edodes (shiitake) appear in ancient texts dating to the Han dynasty (circa 200 BCE–200 CE). The Compendium of Materia Medica and Shen Nong Compendium Medica document their applications for longevity, vitality, and treating various ailments. The term “medicinal mushroom” typically refers to edible or supplemental fungi whose fruiting body and/or mycelium contain compounds with pharmacological activity extending beyond basic nutrition. These aren’t just foods—they’re functional foods with measurable biological effects that researchers continue to characterize. There’s an important distinction between culinary use and therapeutic application. Eating shiitake mushrooms in a stir-fry provides nutritional benefits, but concentrated extracts and standardized preparations—like lentinan injections used in Japanese hospitals or PSK/PSP from turkey tail used throughout East Asia—deliver therapeutic doses of specific compounds. These preparations have been integrated into conventional western medicine in some countries for adjuvant cancer care. The modern surge of interest in medicinal mushrooms began around the 1990s, driven by the growth of functional medicine, integrative oncology, and the expanding global dietary supplements market. China remains the world’s largest producer of cultivated mushrooms, supplying both the culinary and nutraceutical industries. This intersection of traditional use and contemporary research has made medicinal mushrooms a focal point in complementary and integrative health. Of approximately 15,000 known macrofungi species, about 650 have reported medicinal properties. However, only a few dozen have been rigorously studied. This article focuses on the best-characterized mushroom species and their compounds, providing you with the evidence you need to make informed decisions about incorporating these fungi into your health care regimen. Bioactive Compounds in Medicinal Mushrooms The health benefits attributed to medicinal mushrooms stem primarily from complex polysaccharides, terpenoids, proteins, and phenolic compounds concentrated in fungal cell walls and secondary metabolite fractions. Understanding these compounds helps explain why different species and preparations produce varying effects. β-Glucans: The Primary Immunomodulators β-glucans, particularly β-1,3/1,6-glucans, serve as the primary immunomodulatory compounds in most medicinal mushrooms. These complex polysaccharides interact with specific receptors on immune cells: Receptor Cell Types Effects Dectin-1 Macrophages, dendritic cells Pattern recognition, phagocytosis activation CR3 (Complement Receptor 3) Neutrophils, NK cells Enhanced cytotoxicity, complement activation TLRs (Toll-like Receptors) Multiple immune cells Cytokine production, innate immune activation This receptor interaction triggers cascades that enhance the immune response, including increased natural killer cell activity and T cells activation—key components of the body’s defense against pathogens and abnormal cell growth. Terpenoids and Triterpenes Terpenoids, including triterpenes like ganoderic acids from reishi and antcins from Antrodia cinnamomea, represent lipid-like molecules with distinct pharmacological profiles. Research demonstrates their: Anti-inflammatory activity through NF-κB pathway modulation Hepatoprotective effects in animal models Potential antitumor actions through cell cycle arrest and apoptosis induction Anticholinesterase activity relevant to neurodegenerative conditions These compounds typically require alcohol extraction to concentrate effectively, which is why dual-extraction methods (water plus alcohol) are often preferred for species rich in both polysaccharides and triterpenes. Fungal Immunomodulatory Proteins and Other Compounds Several smaller but potent molecules contribute to medicinal mushroom effects: Fungal Immunomodulatory Proteins (FIPs) : Modulate cytokine release and influence Th1/Th2 immune balance Lectins and Glycoproteins : Show direct cytotoxicity toward tumor cells in vitro Phenolics : Contribute antioxidant properties and anti-inflammatory effects Ergosterol : Converts to vitamin D2 under UV exposure Fatty Acids : Support cardiometabolic health Many studies still use crude extracts rather than purified compounds, making it challenging to attribute specific effects to individual molecules. This complexity also suggests potential synergistic interactions between multiple bioactive metabolites within each mushroom species. Key Medicinal Mushroom Species and Their Evidence This section profiles the most widely researched medicinal mushroom species, examining both traditional uses and modern scientific data from in vitro, animal, and human studies. Each subsection outlines primary bioactive compounds, main health targets, and the current level of clinical evidence available through the mid-2020s. The emphasis falls on species with substantial research backing, including Coriolus versicolor (turkey tail), Ganoderma lucidum (reishi), Lentinula edodes (shiitake), Pleurotus spp. (oyster mushrooms), Grifola frondosa (maitake), Hericium erinaceus (lion’s mane), Antrodia cinnamomea, and Agaricus species. Important : These summaries are informational and do not replace individualized medical advice. People with cancer, autoimmune disease, or those taking immunosuppressive drugs or anticoagulants should consult healthcare professionals before using medicinal mushroom products. Coriolus versicolor (Turkey Tail) Coriolus versicolor, also known as Trametes versicolor or “turkey tail,” is a polypore mushroom common in temperate forests worldwide. It holds a prominent place in Chinese and Japanese medicine for immune support and has become one of the most studied species for adjunctive cancer care. Two standardized extracts have driven most clinical research: Extract Origin Approval Status PSK (Polysaccharide-K/Krestin) Japan Approved since 1977 as cancer adjuvant PSP (Polysaccharopeptide) China Widely used; multiple approved drugs Both extracts are rich in β-glucans bound to proteins, distinguishing them from simpler polysaccharide preparations. At least 12 Coriolus versicolor-based drugs have been approved by China’s State Administration of Food and Drugs for integrated cancer therapy. Preclinical Findings Laboratory and animal studies demonstrate that PSP and PSK: Stimulate macrophages, dendritic cells, T cells, and NK cells Increase cytokine production (IL-2, IFN-γ) Induce apoptosis and cell cycle arrest in various tumor cell lines Arrest cancer cells in the pre-G0/G1 phase Enhance immune response against human breast cancer cells and other malignancies Human Clinical Evidence PSK has been administered safely to thousands of cancer patients in Japan since the mid-1970s. Key trial results include: Gastric cancer : Japanese trials from the 1980s-1990s showed improved survival and reduced recurrence when PSK was added to chemotherapy Colorectal cancer : Similar adjuvant benefits observed Lung and breast cancer : More recent results have been mixed, highlighting the need for cancer-type-specific protocols PSK appears to enhance NK cell and T cells activity while producing minimal side effects—making it attractive for patients already dealing with treatment toxicity. Practical Considerations Today, oral turkey tail extracts are commonly used in integrative oncology protocols. However, product quality and PSK/PSP standardization vary significantly outside regulated pharmaceutical preparations. Consumers should seek products specifying extract type and polysaccharide content. Ganoderma lucidum (Reishi) Ganoderma lucidum, known as reishi in Japanese or lingzhi in Chinese, has been called the “mushroom of immortality” for centuries. Classical materia medica texts describe its use for fatigue, longevity, and liver and immune support. Key Active Compounds The therapeutic effects of this medical mushroom derive from: Triterpenes : Ganoderic and lucidenic acids with anti-inflammatory and hepatoprotective properties High-molecular-weight β-glucans : Immunomodulatory polysaccharides Effective extraction typically requires both hot water (for polysaccharides) and alcohol (for triterpenes), explaining the popularity of dual-extract supplements. Preclinical Evidence Research in cell and animal models shows reishi extracts can: Inhibit tumor cell proliferation Induce apoptosis in cancer cells Reduce metastasis-related signaling Modulate inflammatory pathways including NF-κB Provide cardioprotective and hepatoprotective effects Exhibit anticholinesterase activity relevant to conditions like Alzheimer’s disease Human Clinical Data Several small randomized and open-label studies from the 2000s-2010s examined reishi in cancer patients. Findings include: Improved quality of life measures Enhanced immune markers (increased NK cell activity) Fatigue reduction in patients with lung, colorectal, or breast cancer Limited impact on hard survival endpoints Beyond oncology, reishi has been studied in metabolic syndrome, hypertension, and neurasthenia. Some controlled trials showed improvements in well being and sleep quality, though effects on blood glucose and lipids remained inconsistent across studies. Lentinula edodes (Shiitake) Shiitake mushrooms represent both a globally popular culinary ingredient and a source of well-characterized medicinal compounds. The edible mushroom appears regularly in Asian cuisine while its extracts have earned pharmaceutical status in some countries. Lentinan: The Key Compound Lentinan, a β-1,3-glucan isolated from shiitake fruiting bodies in the 1960s, has been used in Japan as an injectable adjuvant for gastric cancer and other malignancies. Clinical studies from the 1970s-1990s demonstrated: Enhanced survival in some chemotherapy regimens Improved immune function during treatment Stimulation of dendritic cells, T cells, and NK cells Reduced tumor angiogenesis through cytokine modulation Oral Supplements Active Hexose Correlated Compound (AHCC), a shiitake-derived oral supplement, has generated significant research interest. Small human studies indicate: Immune enhancement Possible benefits in reducing viral infection risk Potential support during cancer treatment Larger, independent trials are still needed to confirm these effects. The national cancer institute and other organizations continue to evaluate shiitake-derived compounds in clinical trials. Cardiometabolic Benefits Shiitake components extend beyond cancer support. Eritadenine, a unique compound in shiitake mushrooms, can help lower cholesterol. Regular dietary intake has been associated with favorable lipid profiles and reduced inflammatory markers, supporting overall health. Pleurotus Species (Oyster Mushrooms) Pleurotus ostreatus and related oyster mushrooms combine culinary appeal with documented medicinal properties. These fungi are among the most commercially cultivated worldwide, making them accessible for both dietary and supplemental use. Research Profile Preclinical work demonstrates Pleurotus polysaccharides and extracts: Enhance macrophage activity Induce tumor cell cycle arrest Suppress cancer cell motility and migration Modulate PI3K/Akt and p53-related signaling pathways Show superior efficacy against breast and colon cancer cells compared to some other mushrooms in comparative assays Clinical Evidence Human trials from the 2000s-2010s showed that regular consumption or supplementation with Pleurotus ostreatus can: Outcome Effect Blood glucose Reduced in type 2 diabetes Total cholesterol Decreased LDL cholesterol Lowered Triglycerides Reduced Blood pressure Modest reductions Pleuran, a β-glucan fraction from Pleurotus, has been tested in randomized clinical trial settings with encouraging results: Reduced frequency of respiratory infections in children and adults Decreased herpes simplex symptoms No notable adverse effects Oyster mushrooms represent a practical, food-first option for cardiometabolic support. They can promote health through regular dietary inclusion, though supplement doses differ significantly from culinary portions. Grifola frondosa (Maitake) Grifola frondosa, known as maitake or “dancing mushroom,” enjoys both culinary and medicinal status in Japan and China. Research has focused extensively on its D-fraction and related β-glucan proteoglycans. Preclinical Findings D-fraction and MD-fraction have demonstrated ability to: Activate macrophages and NK cells Induce apoptosis in tumor cells Inhibit tumor growth and metastasis in breast, liver, and other cancer models Modulate transforming growth factor and other cytokines Clinical Studies Small open-label and pilot trials from the 1990s-2000s suggest that maitake D-fraction, taken orally alongside conventional treatment, may: Improve immune parameters Reduce tumor markers Possibly slow disease progression in some cancers Metabolic Effects Maitake polysaccharide fractions may improve insulin sensitivity by modulating the PI3K/Akt pathway. This points to potential antidiabetic utility, though larger trials are needed. Safety data indicate maitake is generally well tolerated. However, people on antidiabetic or immunomodulating medications should consult a clinician before starting high-dose extracts due to possible additive effects. Hericium erinaceus (Lion’s Mane) Hericium erinaceus, or lion’s mane, is a distinctive white, cascading mushroom traditionally used in East Asia for digestive and nervous system health. It has gained substantial popularity in nootropic communities for cognitive support. Key Compounds Lion’s mane contains unique bioactive molecules: Hericenones : Found in fruiting bodies Erinacines : Found in mycelium Both compound classes can cross the blood-brain barrier and induce nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) production—critical proteins for neuronal health and plasticity. Animal Research Studies demonstrate lion’s mane: Protects against neuronal damage in Parkinson’s disease models Reduces damage from ischemic stroke Promotes peripheral nerve injury recovery Decreases neuroinflammation via NF-κB and Nrf2/HO-1 pathway modulation Human Clinical Evidence Japanese trials from 2009 onward examined lion’s mane in cognitive health: Older adults with mild cognitive impairment taking lion’s mane powder for 12-16 weeks showed modest improvement in cognitive scores versus placebo Some studies indicate benefits for mood, anxiety, and sleep Research in menopausal symptoms showed promising results These findings support lion’s mane as a potential tool for brain and mental health, though larger and longer trials are necessary before firm clinical recommendations can be made. Antrodia cinnamomea Antrodia cinnamomea (also called Taiwanofungus camphoratus) is a rare medicinal food endemic to Taiwan. Traditional use focuses on liver protection, hangover recovery, and cancer support. The fungus is typically cultivated on Cinnamomum kanehirae wood, which influences its chemical profile. Active Compounds Major bioactive molecules include triterpenoids: Antcin A, B, C, and K Exhibit anti-inflammatory, hepatoprotective, and antitumor activities Preclinical Mechanisms Antrodia extracts have been shown to: Induce cell cycle arrest and autophagy in cancer cells Trigger endoplasmic reticulum stress Inhibit epithelial-mesenchymal transition (EMT) Reduce invasiveness and metastasis in breast and liver cancer models Show decreased expression of pro-metastatic genes Clinical Status Early human trial data in oncology indicate improvements in fatigue and sleep, along with some immune markers. However, no clear survival benefit has been established, highlighting the need for better-designed randomized controlled studies with standardized preparations. Note : Antrodia products on the market vary widely in authenticity and potency. Sourcing verification is critical for both practitioners and consumers. Agaricus Species (Button and Blazei) This category includes two distinct species with different medicinal profiles: Agaricus bisporus  (button/portobello mushroom) The most commonly cultivated mushroom in Western countries Contains β-glucans, ergosterol (vitamin D2 precursor), and phenolic antioxidants Human data suggest benefits for cardiovascular risk and PSA modulation in some prostate cancer studies Agaricus blazei Murrill  (also Agaricus subrufescens or Himematsutake) More pronounced medicinal applications β-glucan-rich extracts studied for immune enhancement and antitumor effects Investigated for supportive roles in diabetes and chronic viral infections Clinical Trial Results Randomized controlled trials show Agaricus blazei extracts can: Increase NK cell activity Improve chemotherapy tolerance in gynecological cancer patients Improve insulin resistance in type 2 diabetes Safety Considerations Certain unrefined Agaricus products have been associated with: Liver enzyme elevations Allergic reactions in susceptible individuals Attention to dosage, preparation type, and monitoring is essential, particularly with wild mushrooms or less-regulated products. Clinical Applications and Medical Evidence While much medicinal mushroom research remains preclinical, several decades of human trials now exist. These studies—mostly small and heterogeneous—have investigated applications in cancer, metabolic disease, brain health, and infection prevention. Importantly, most clinical products used in East Asian hospitals (PSK, lentinan injections) are more standardized than many Western dietary supplements. This difference complicates extrapolation of study results to commercial over-the-counter products available through integrative health approaches. Mushrooms and Cancer: Adjuvant Uses Integrative medicine focuses on using medicinal mushrooms as adjuvants in oncology. The goal is enhancing immune response, improving quality of life, and reducing treatment side effects—not replacing surgery, chemotherapy, or radiotherapy. Key Clinical Examples Mushroom/Extract Cancer Type Key Findings PSK (Turkey Tail) Gastric, colorectal Improved survival, reduced recurrence Lentinan (Shiitake) Gastric, lung Enhanced immune markers, some survival benefit Maitake D-fraction Various Enhanced NK activity, better symptom control Agaricus blazei Gynecological Improved chemotherapy tolerance Mixed Results and Limitations Some trials showed limited effects: Ganoderma lucidum in prostate cancer showed little effect on progression Agaricus blazei results varied by cancer type Species, dosing, cancer type, and stage strongly influence outcomes. The AndoSan™ mixture (Agaricus blazei, Grifola frondosa, Hericium erinaceus) improved immune cell profiles in a small multiple myeloma trial, but replication is needed. Critical Guidance Cancer patients should only start medicinal mushroom supplements in coordination with their oncology team. Potential interactions exist with: Immunotherapy agents Chemotherapy drugs Anticoagulants Integrative medicine seeks to complement rather than conflict with standard care, and healthcare professionals can help navigate these considerations. Mushrooms in Metabolic and Cardiovascular Health Evidence suggests certain mushrooms may support metabolic health when used alongside diet and lifestyle changes. Key species include Pleurotus spp., maitake, Agaricus blazei, and Agaricus bisporus. Specific Trial Findings Agaricus blazei extract improved insulin resistance in type 2 diabetes randomized studies Pleurotus ostreatus consumption lowered total cholesterol and blood pressure Regular intake of shiitake mushrooms associated with favorable lipid profiles Important Caveats Results aren’t uniform across species. Some Ganoderma lucidum trials in metabolic syndrome did not show significant improvements in blood lipids or glucose. Generalizing findings from one mushroom to all would be a mistake. Medicinal mushrooms should be framed as part of broader lifestyle and medical plans for metabolic disease—not standalone treatments. Patients on hypoglycemic medications should monitor for additive effects. Mushrooms and Brain, Mood, and Nerve Health Interest in medicinal mushrooms for brain health has surged in the 21st century. Lion’s mane and reishi have received the most attention for cognitive and mood outcomes. Lion’s Mane Clinical Data Small Japanese randomized, double-blind, placebo-controlled trials showed: Improvements in cognitive function in mild cognitive impairment after 12-16 weeks Reductions in depression and anxiety scores in other small cohorts Reishi Studies Ganoderma lucidum has been studied in patients with neurasthenia and chronic fatigue: Improved measures of well-being Reduced fatigue Modest sample sizes limit generalizability Mechanistic Insights Animal and in vitro studies reveal: NGF and BDNF upregulation Myelin repair support Reduced neuroinflammation Translating these findings to long-term human brain health requires more rigorous trials. Individuals with neurological diseases or those taking psychiatric medications should consult their neurologist or psychiatrist before adding potent mushroom extracts. Other Clinical Indications and Immune Support Beyond cancer and metabolic disease, medicinal mushrooms support general immune resilience and may reduce infection frequency. Infection Prevention Randomized controlled trials with Pleuran (Pleurotus-derived) showed: Reduced recurrent respiratory infections in children and adults Shortened acute infection duration Decreased herpes simplex symptoms No notable adverse events Gut Microbiome Effects Emerging studies demonstrate mushroom consumption can: Shift microbial composition favorably Increase short-chain fatty acid producers Improve mucosal immunity (increased IgA levels) Autoimmune Considerations While mushrooms may support immune balance, they can theoretically exacerbate autoimmune conditions in rare cases. People with autoimmune disease should introduce them cautiously and with medical guidance. This reflects integrative medicine aims to address the whole person while avoiding preventive measures that could backfire. From Forest to Capsule: Quality, Forms, and Safety Clinical outcomes depend not only on the mushroom species but also on cultivation, processing, extraction, and standardization. Product quality represents a crucial consideration that can mean the difference between therapeutic benefit and wasted money. Consumers and practitioners should seek: Transparent labeling Third-party testing (heavy metals, pesticides) Clearly stated β-glucan and active compound levels Mycelium vs. Fruiting Body Understanding this distinction is essential for informed purchasing decisions. Fruiting Body The visible “mushroom” growing above ground or on wood Generally higher concentrations of β-glucans More triterpenoids in species like reishi Basis for most traditional preparations and East Asian clinical trials Mycelium Root-like network of fungal filaments colonizing the substrate May contain unique compounds (e.g., erinacines in lion’s mane mycelium) Many Western products use mycelium grown on grain (rice, oats) The Grain Problem Mycelium-on-grain products are dried and milled with their substrate. This can: Dilute active compounds with residual starch Reduce polysaccharide concentration significantly Create products with more filler than fungus When therapeutic effects are desired, choose products that: Specify “fruiting body extract” List β-glucan percentages (aim for 15%+ for most species) Avoid vague terms like “mushroom complex” without details Mycelium isn’t inherently inferior—but claims should match the form actually used in supporting research. Supplement Forms, Dosage, and Practical Use Medicinal mushrooms come in various formats: Form Best For Notes Dried whole mushrooms Culinary use, teas Lower concentration but food-matrix benefits Hot-water extracts Polysaccharide concentration Standard for β-glucan extraction Dual extracts Combined polysaccharide + triterpenoid Ideal for reishi, chaga Capsules/tablets Convenience, standardized dosing Check extraction method Tinctures Alcohol-soluble compounds Good for triterpenes Mushroom powder Versatility Quality varies widely Typical Dosage Ranges Study doses vary, but common ranges include: Extract powders (reishi, turkey tail): 1-3 g/day Dried culinary mushrooms: 3-5 g/day PSK (pharmaceutical): 3 g/day in clinical protocols Practical Integration For general health: Add shiitake, maitake, and oyster mushrooms to meals several times weekly Consider this a foundation for optimal health For targeted support: Reserve concentrated extracts for specific health goals Work under professional supervision for serious conditions Start at lower doses and titrate up while tracking responses Choose organic or carefully cultivated products to reduce pesticide and heavy metal exposure, particularly for long-term, high-dose use. Safety, Side Effects, and Interactions Most edible medicinal mushrooms are safe as foods for the general population. Traditional use and modern studies confirm low toxicity profiles. However, concentrated extracts can have pharmacological effects meriting caution. Common Mild Side Effects Some trials and case reports note: Digestive upset Loose stools Skin rashes Headaches These typically resolve with dose reduction or discontinuation. Potential Drug Interactions Mushroom Effect Medication Category Concern Immunostimulant Immunosuppressants (transplant drugs) Possible interference Blood pressure effects Antihypertensives Additive effects Anticoagulant properties Warfarin, anticoagulants Bleeding risk Hypoglycemic effects Diabetes medications Additive blood sugar lowering High-Risk Groups The following should only use medicinal mushroom extracts under medical supervision: People with autoimmune diseases Those on chemotherapy or biologic agents Transplant recipients Pregnant or breastfeeding individuals Children Product purity matters significantly. Contamination with heavy metals, mycotoxins, or misidentified species has been documented in poorly regulated markets. Verified sourcing and independent testing are essential, particularly for products marketed through complementary medicine channels. Discussion: Promise, Limitations, and Research Gaps Medicinal mushrooms show strong promise in immunomodulation, supportive oncology, metabolic health, and neuroprotection. However, most robust data still come from preclinical and small clinical studies. Enthusiasm must be tempered with honest acknowledgment of what we don’t yet know. Key Challenges Several factors complicate the research landscape: Heterogeneity : Mushroom strains, cultivation conditions, extraction methods, and dosing vary dramatically across studies Standardization gap : Pharmaceutical-grade preparations (PSK, lentinan) differ substantially from unregulated dietary supplements Labeling inconsistency : Many products don’t accurately reflect their contents Methodological Limitations Existing clinical trials often feature: Small sample sizes Short follow-up periods Lack of proper blinding or controls Insufficient adverse event reporting Unclear documentation of concomitant therapies Research Priorities Moving the field forward requires: Large randomized controlled trials in specific cancers and chronic diseases Head-to-head comparisons of fruiting body versus mycelium products Deeper mechanistic studies on synergistic multi-species formulas Standardization protocols for clinical research Despite these limitations, integrative medicine practices increasingly incorporate medicinal mushrooms where evidence supports their use. The American Herbal Pharmacopoeia and similar organizations continue developing quality standards that may improve the landscape. Conclusion Medicinal mushrooms occupy a unique space between food and medicine, offering nutrient density plus pharmacologically active compounds that can support immune, metabolic, and neurological health. From the healing process documented in ancient texts to modern randomized clinical trial data, these fungi have demonstrated real therapeutic potential. Current evidence justifies the thoughtful use of well-characterized mushroom preparations as adjuncts—especially in oncology, cardiometabolic care, and cognitive support. They work alongside, not instead of, conventional treatments. Integrative health approaches that incorporate these fungi show promise for enhancing quality of life and supporting the human body’s natural defenses. Quality matters enormously. Species identification, cultivation practices, extraction methods, and standardization of β-glucans and other actives should guide both consumer and clinician choices. A $20 supplement with unstandardized mycelium-on-grain isn’t equivalent to pharmaceutical PSK or properly extracted fruiting body preparations. Collaboration between practitioners of conventional and integrative medicine ensures mushroom-based interventions are coordinated, monitored, and tailored to individual risk profiles. Whether you’re a health care professional exploring complementary therapies or someone seeking preventive measures for chronic diseases, understanding both the promise and limitations of medicinal mushrooms enables informed decision-making. Advances in mycology, pharmacology, and clinical research continue to validate centuries of traditional use. Music therapy, tai chi, massage therapy, and massage therapists all have their place in integrative approaches—and medicinal mushrooms are earning theirs. The coming decades may transform select species into validated nutraceuticals and, in some cases, drug leads that reshape how we approach health issues from cancer to cognitive decline. The national center for complementary and integrative health and similar organizations worldwide continue monitoring this evolving field. For now, medicinal mushrooms represent a legitimate, if still developing, tool in the broader toolkit of well coordinated care. The complementary therapies editorial board and researchers globally are working to fill the evidence gaps that remain. Frequently Asked Questions (FAQ) Can medicinal mushrooms cure cancer or replace chemotherapy? No high-quality evidence supports mushrooms as stand-alone cancer cures. Clinical trials consistently position them as adjuvants—supporting immune function, improving quality of life, and potentially enhancing treatment tolerance. They should only be used alongside conventional cancer treatment under oncologist supervision. The most robust evidence comes from PSK and lentinan used in East Asian hospitals as part of comprehensive treatment protocols, not as replacements for standard care. How long does it take to notice benefits from medicinal mushroom supplements? Timelines vary considerably by health goal. Immune and energy effects may become noticeable within 2-4 weeks of consistent use. Cognitive or metabolic changes typically require 2-3 months of regular supplementation. However, these benefits always occur in the context of broader lifestyle factors—sleep, diet, exercise, stress management—and medical care. Some trial participants showed improvements only after 12-16 weeks of daily use, so patience and consistency matter. Are medicinal mushrooms safe during pregnancy and breastfeeding? Culinary mushrooms like shiitake and button mushrooms are generally safe as foods during pregnancy. However, concentrated extracts and supplements lack sufficient safety data for use in pregnancy or lactation. The prudent approach is to avoid high-dose supplements during these periods unless specifically recommended by a healthcare provider. Standard culinary use can continue as part of a varied diet, but therapeutic dosing should wait. Can I take multiple medicinal mushrooms together? Traditional formulas and some modern studies use combinations—for example, reishi with shiitake and maitake. Multi-species products like AndoSan™ have been studied in clinical settings with positive results. However, stacking many products at high doses may increase side-effect risk or create unpredictable interactions. A reasonable approach is starting with one or two well-chosen mushrooms, monitoring your response over several weeks, and adding others only if needed and tolerated. How do I choose a high-quality medicinal mushroom supplement? Look for these markers of quality: Clear species names (both Latin and common) Explicit disclosure of fruiting body versus mycelium Standardized β-glucan content (ideally 15%+ for most species) Absence of unnecessary fillers or flow agents Organic certification or documented cultivation practices Third-party testing certificates for potency and contaminants (heavy metals, pesticides) Avoid products with vague labels like “proprietary mushroom blend” without specific percentages, or those that don’t clarify whether they use fruiting body or mycelium-on-grain. About the Author About Dr. Kim Dr. Yoon Hang "John" Kim, residential fellowship trained in integrative medicine at University of Arizona and a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL, where he provided care to rural and underserved populations, Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible to patients regardless of location. His approach combines functional medicine lab testing with complementary therapies such as meditation, yoga, tai chi, and lifestyle interventions using food and physical activity as medicine, addressing the root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a master’s in public health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, he has also contributed to the field as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. With clinical interests in autoimmune conditions, chronic pain, integrative oncology, and gastrointestinal disorders, Dr. Kim specializes in treating complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID symptoms, and toxic mold illness, and has authored two books and over 20 articles while helping establish integrative medicine practices across various institutions. Professional Inquiries:   www.yoonhangkim.com Clinical Inquiries:   www.directintegrativecare.com

Quick Answer: Does LDN Cause Hair Loss? No direct evidence exists that LDN causes hair loss as a primary side effect Clinical trials consistently list vivid dreams, sleep changes, and headaches as the most common side effects Hair loss in LDN patients typically relates to the underlying autoimmune condition, thyroid imbalance, or nutritional deficiency LDN may actually help certain types of autoimmune hair loss, with studies showing disease stabilization in 70-80% of patients with frontal fibrosing alopecia Timing matters: Hair loss occurring 2-3 months after a trigger may be Telogen Effluvium, a temporary stress response The relationship between low-dose naltrexone and hair health is far more complex than a simple cause-and-effect. For most people experiencing hair thinning while on LDN, the real culprit is usually the autoimmune condition, thyroid imbalance, nutritional deficiency, or stress that prompted LDN treatment in the first place. I’m Dr. Yoon Hang Kim, a board-certified physician specializing in integrative medicine and functional medicine who has prescribed and refined LDN protocols for over two decades across conditions ranging from autoimmune disorders to chronic pain. In my extensive clinical experience with patients concerned about LDN and hair loss, I’ve found that most cases stem from undertreated thyroid issues, iron deficiency, or the autoimmune process itself rather than the medication. Let’s explore what the science really shows and how to approach hair health when taking LDN. Does LDN Cause Hair Loss? Unpacking the Evidence The scientific evidence regarding whether LDN causes hair loss is nuanced. While some individuals report hair changes on LDN, this isn’t a commonly recognized side effect in clinical studies. Standard-dose naltrexone (50mg and above) has occasionally been associated with hair loss, though it’s uncommon. Low-dose naltrexone (0.5-4.5mg) works through an entirely different mechanism, focusing on immune modulation and endorphin upregulation rather than sustained opioid receptor blockade. Published studies investigating LDN across fibromyalgia, multiple sclerosis, and inflammatory bowel disease consistently track adverse events but rarely mention hair loss among significant findings (Younger et al., 2014; Toljan & Vrooman, 2023). The known side effects of LDN are typically mild and transient: vivid dreams occur in approximately 20-30% of patients, along with occasional sleep disturbances and headaches. These typically resolve within the first few weeks of treatment as the body adjusts. Potential Indirect Links While LDN doesn’t directly cause hair loss, indirect connections may exist. Temporary hormonal shifts or endocrine adjustments during the initial weeks of LDN therapy could, in sensitive individuals, contribute to hair shedding. More commonly, patients experiencing hair loss concerns while on LDN may have Telogen Effluvium—a stress-induced shedding pattern that appears 2-3 months after a physiological trigger. The trigger may have been the illness that led them to seek LDN treatment in the first place. Anecdotal Reports vs. Clinical Data Patient forums contain stories linking LDN to hair loss, but controlled trials tell a different story. Multiple studies across fibromyalgia, multiple sclerosis, and Crohn’s disease carefully track adverse events yet consistently omit hair loss from significant findings. This discrepancy suggests anecdotal reports likely reflect underlying conditions rather than LDN effects. The Real Culprits: When It’s Not the LDN In my practice at www.directintegrativecare.com , serving patients across Iowa, Illinois, Missouri, Florida, Georgia, and Texas, I find that hair loss often signals deeper imbalances rather than medication effects. The conditions that bring patients to LDN in the first place frequently cause hair loss themselves. Type of Hair Loss Typical Triggers/Causes Telogen Effluvium Temporary diffuse shedding 2-3 months after stress, illness, surgery, or medication changes Autoimmune Conditions Hashimoto’s thyroiditis, Alopecia Areata, and Lupus can directly attack hair follicles Thyroid Imbalance Both hypothyroidism and hyperthyroidism cause dry, brittle, diffusely thinning hair Iron Deficiency Low ferritin impairs hair follicle proliferation even without frank anemia Nutritional Deficiencies Low zinc, vitamin D, B12, and protein all impair healthy hair growth Iron Deficiency: A Hidden Cause of Hair Loss When patients come to me worried that LDN is causing their hair loss, one of the first things I investigate is their iron status. Iron deficiency is remarkably common—especially in women of childbearing age—and frequently flies under the radar because most practitioners only check hemoglobin. You can have perfectly normal hemoglobin and still be profoundly iron deficient. The Ferritin-Hair Connection Iron is essential for DNA synthesis in rapidly dividing cells, and hair follicle matrix cells are among the fastest-dividing cells in the human body. When iron stores drop, your body prioritizes vital organs, and hair follicles lose the competition. Research from China examining 193 patients with telogen effluvium found that serum ferritin levels were significantly lower in hair loss patients compared to healthy controls, with an optimal diagnostic cutoff around 24.5 ng/mL (Cheng et al., 2021). Here’s what I’ve learned from two decades of clinical practice: the laboratory “normal” range for ferritin is not the same as the “optimal” range for hair health. Most labs report ferritin as normal anywhere from 12-150 ng/mL in women. But in functional medicine, we’ve found that hair follicles often need ferritin levels above 70 ng/mL to function optimally (Rushton, 2002). Who’s at Risk? A systematic review and meta-analysis examining iron deficiency in women with nonscarring alopecia found that approximately 21% of women with hair loss had ferritin deficiency, and the prevalence increased substantially when using a higher threshold of 30-40 ng/mL (Gafter-Gvili & Cohen, 2022). Risk factors for iron deficiency that I commonly see in my practice include heavy menstrual periods, vegetarian or vegan diets without adequate supplementation, gastrointestinal conditions affecting absorption (particularly relevant for my MCAS patients), chronic inflammation, and recent blood donation. The Functional Medicine Approach to Iron Assessment When evaluating a patient with hair loss, I order a comprehensive iron panel rather than just ferritin alone. This includes serum iron, total iron-binding capacity (TIBC), transferrin saturation, and ferritin. Ferritin can be falsely elevated in inflammatory conditions—particularly relevant for patients with autoimmune conditions or chronic infections—so the complete picture matters. For my patients with low ferritin and hair loss, I typically recommend iron supplementation with vitamin C to enhance absorption, alongside addressing any underlying causes of deficiency. Patience is essential: hair growth cycles are long, and it typically takes 3-6 months of optimized iron stores before visible improvement occurs. The Flip Side: Can LDN Actually Treat Hair Loss? While some people worry about LDN causing hair loss, a growing body of evidence suggests it may actually be an effective treatment for certain types of hair loss, particularly those with an autoimmune component. By modulating the immune system and reducing inflammation, LDN can help calm the overactive immune response that targets and damages hair follicles. Evidence for LDN in Autoimmune Alopecia LDN’s ability to increase endorphin production and regulate T-regulatory cells can be particularly beneficial for autoimmune-driven hair loss. The most compelling evidence comes from studies on frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP), both scarring forms of alopecia. A retrospective study from the University of Pittsburgh examining 52 patients with FFA and LPP who had failed multiple prior treatments found remarkable results with LDN. For patients with FFA, 75% achieved disease stability within 6.4 months, with significant improvements in pruritus and perifollicular erythema. For LPP patients, 65% achieved disease stability within 7.3 months (Shaker et al., 2024). A prospective open-label study from Washington University enrolled 43 patients with FFA and LPP and followed them for 12 months on 3mg daily LDN. The frontal hairline remained stable in FFA patients throughout the study period, with significant improvements in itching, burning, and erythema scores (Hamel et al., 2023). Conditions Where LDN Shows Promise Alopecia Areata: This autoimmune condition where the body attacks its own hair follicles, causing patchy hair loss, may benefit from LDN’s immune-modulating effects. While formal trials are limited, the mechanism of action aligns well with the disease pathophysiology (Mesinkovska, 2018). Lichen Planopilaris and Frontal Fibrosing Alopecia: These scarring alopecias characterized by inflammation show the most robust evidence for LDN benefit. Multiple studies demonstrate that LDN can halt progression and, in some cases, promote regrowth in follicles not yet permanently damaged. Trichodynia (Scalp Pain/Discomfort): Even in patients where LDN doesn’t produce measurable hair regrowth, many report significant improvement in scalp discomfort, itching, and burning (Wismuth et al., 2019). Dosage and Timelines for Hair Restoration When used for hair loss, LDN is typically prescribed in the same low-dose range as for other autoimmune conditions. Based on my clinical experience and the published literature, I usually start patients at 1.5mg and gradually increase to a target dose of 4.5mg per day. The University of Pittsburgh study used 4.5mg daily in most patients, while the Washington University study used 3mg daily—both with positive outcomes. Patience is essential. Hair growth cycles are long, typically 2-7 years for scalp hair. While some patients notice a reduction in shedding and scalp inflammation within 4-6 weeks, visible regrowth usually takes 3-6 months or longer. Optimal results are often seen after at least 6-12 months of consistent use. Practical Summary: LDN and Hair Health Clinical Scenario Recommended Approach Hair loss started on LDN Investigate underlying causes: thyroid, ferritin, nutritional status, autoimmune markers Autoimmune hair loss (FFA/LPP) LDN 3-4.5mg daily; expect 6+ months for disease stabilization Low ferritin with hair loss Optimize ferritin to >70 ng/mL; continue LDN if indicated for underlying condition Telogen effluvium pattern Identify trigger (illness, stress, surgery); reassure that LDN is unlikely the cause; typically self-resolving Conclusion - Does LDN Cause Hair Loss? Integrative Medicine & Functional Medicine Perspective The question “Does LDN cause hair loss?” has a nuanced answer. Based on published research and my two decades of clinical experience, LDN does not appear to directly cause hair loss. Rather, patients experiencing hair changes while on LDN typically have underlying conditions—autoimmune disease, thyroid dysfunction, iron deficiency, or nutritional imbalances—that are the true culprits. In fact, for patients with autoimmune-related hair loss like frontal fibrosing alopecia, lichen planopilaris, and potentially alopecia areata, LDN may be part of the solution rather than the problem. The key is individualized assessment, addressing all contributing factors, and working with a practitioner experienced in both LDN and the complex interplay of autoimmunity, hormones, and nutritional status. For patients struggling with hair loss alongside chronic complex conditions, working with a physician experienced in LDN, integrative medicine, and functional medicine can make the difference between frustration and meaningful improvement. About the Author Yoon Hang Kim, MD is a board-certified preventive medicine physician specializing in integrative and functional medicine. A graduate of the University of Arizona Integrative Medicine Fellowship, Dr. Kim has been prescribing LDN for over two decades and has presented at multiple LDN Research Trust conferences internationally. He is the author of two books on LDN therapy and practices telemedicine through www.directintegrativecare.com , serving patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. Website: www.directintegrativecare.com References Cheng, T., Fang, H., Wang, Y., Wang, Y., Yang, Z., Wu, R., & Yang, D. (2021). The diagnostic value of serum ferritin for telogen effluvium: A cross-sectional comparative study. Clinical, Cosmetic and Investigational Dermatology, 14 , 137-141. https://doi.org/10.2147/CCID.S291170 Gafter-Gvili, A., & Cohen, A. (2022). Iron deficiency and nonscarring alopecia in women: Systematic review and meta-analysis. Skin Appendage Disorders, 8 (2), 83-92. https://doi.org/10.1159/000519952 Hamel, R. K., Chen, L., O’Connell, C., & Mann, C. (2023). Oral low-dose naltrexone in the treatment of frontal fibrosing alopecia and lichen planopilaris: An uncontrolled open-label prospective study. Cureus, 15 (1), e34169. https://doi.org/10.7759/cureus.34169 Mesinkovska, N. A. (2018). Emerging unconventional therapies for alopecia areata. Journal of Investigative Dermatology Symposium Proceedings, 19 (1), S32-S33. https://doi.org/10.1016/j.jisp.2017.10.002 Olsen, E. A., Reed, K. B., Cacchio, P. B., & Caudill, L. (2010). Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. Journal of the American Academy of Dermatology, 63 (6), 991-999. https://doi.org/10.1016/j.jaad.2009.12.006 Rushton, D. H. (2002). Nutritional factors and hair loss. Clinical and Experimental Dermatology, 27 (5), 396-404. https://doi.org/10.1046/j.1365-2230.2002.01076.x Shaker, N., Petrin, C., Miller, D., & Gathers, R. (2024). Attenuation of disease process following treatment with low-dose naltrexone in patients with frontal fibrosing alopecia and lichen planopilaris: A retrospective study. Journal of the American Academy of Dermatology, 91 (2), 421-423. https://doi.org/10.1016/j.jaad.2024.03.028 Toljan, K., & Vrooman, B. (2023). Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions. Biomedicines, 11 (4), 1087. https://doi.org/10.3390/biomedicines11041087 Wismuth, A., Bertolini, M., & Mesinkovska, N. A. (2019). Low-dose naltrexone: A novel adjunctive treatment in symptomatic alopecias? Journal of the American Academy of Dermatology, 81 (4), AB104. https://doi.org/10.1016/j.jaad.2019.06.425 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451-459. https://doi.org/10.1007/s10067-014-2517-2 Disclaimer: This publication is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting or modifying any treatment regimen. © 2025 Yoon Hang Kim, MD | www.directintegrativecare.com

By Yoon Hang Kim, MD, MPH | www.directintegrativecare.com After two decades of practicing integrative medicine, I’ve noticed a pattern that doesn’t fit neatly into conventional diagnostic frameworks. Patient after patient walks into my clinic with a diagnosis of Mast Cell Activation Syndrome—or suspicion of one—and almost invariably, they bring a complex medical history with them. Autoimmune disease. Mold exposure. Lyme disease. Long COVID. Sometimes all of the above. I don’t think that’s coincidence. And increasingly, the research supports what I’m seeing in clinical practice. I’ve come to view MCAS not as a standalone diagnosis, but as an immune derangement syndrome—a final common pathway where multiple immunological insults accumulate until the system reaches a tipping point. The immune system, designed to protect us, loses its ability to self-regulate and return to homeostasis. It forgets how to calm down. What Is Mast Cell Activation Syndrome (MCAS), Really? Mast Cell Activation Syndrome is characterized by mast cells—immune cells found throughout connective tissue—becoming hyperreactive. They release excessive amounts of chemical mediators like histamine, tryptase, prostaglandins, and cytokines in response to stimuli that wouldn’t normally be problematic. This process is called degranulation, and it can be triggered by foods, infections, stress, or environmental exposures. The result is chronic, multisystem inflammation affecting everything from the cardiovascular and gastrointestinal systems to the skin, brain, and respiratory tract. The symptoms are notoriously varied: flushing, hives, abdominal pain, brain fog, fatigue, palpitations, shortness of breath—and dozens more. Some patients experience full anaphylactic reactions with low blood pressure and difficulty breathing. Symptoms typically wax and wane, varying in severity and duration, which makes diagnosis even trickier. To meet diagnostic criteria, patients need systemic symptoms involving two or more organ systems. This heterogeneity makes MCAS both underdiagnosed and overdiagnosed—patients suffer for years without answers, while others receive the label without meeting strict criteria. A 2024 study from the Karolinska Institute evaluated 703 patients with suspected mast cell disorders and found that only 4.4% met strict criteria for idiopathic MCAS. This tells us two things: we need better diagnostic tools, and we need to look deeper at what’s actually driving mast cell dysfunction in these patients. Diagnosis and Testing for MCAS Let me be straight with you: diagnosing MCAS is genuinely difficult. Many of my patients have seen five, ten, even fifteen specialists before landing in my office. That’s not because previous doctors were incompetent—it’s because MCAS symptoms overlap with so many other conditions, and the testing isn’t straightforward. The diagnosis starts where good medicine always starts: a thorough history and physical exam. I’m listening for patterns—episodic flushing, GI symptoms that don’t follow typical patterns, unexplained allergic-type reactions, chronic pain that doesn’t fit neatly into other diagnoses. I’m also looking at the whole person: physical symptoms, yes, but also stress levels, sleep, emotional health. These factors matter more than many practitioners realize. Laboratory testing focuses on measuring mast cell mediators—tryptase, histamine, and prostaglandin metabolites—released during degranulation episodes. Serum tryptase and urinary mediator testing are the standard tools. In some cases, bone marrow biopsy may be needed to rule out systemic mastocytosis, which is a different (and more serious) condition. Here’s what I tell patients: we also need to rule out what MCAS isn’t. That means allergy testing to distinguish true IgE-mediated allergies from mast cell dysfunction. It means considering other conditions—including serious ones like cancer—that can mimic MCAS symptoms. Good diagnosis is as much about ruling things out as ruling things in. Sometimes the diagnosis becomes clearer through treatment response. When patients improve significantly on H1/H2 antihistamines and mast cell stabilizers, that tells us something important. It’s not a perfect test, but clinical response matters. What I’ve found essential is building a real partnership with patients. MCAS management requires ongoing adjustments based on individual responses. It’s not a “one prescription and done” situation. Beyond medications, I often integrate approaches like medical acupuncture and mind-body techniques to support overall healing—not as replacements for evidence-based treatment, but as complements to it. The Multiple Hits Model in Diagnosing MCAS Here’s what I’ve observed clinically: MCAS rarely emerges from a single trigger. Instead, patients typically present with a history of overlapping immune challenges—what I call “hits” to the system. Stack enough of these hits, and the immune system tips into chronic dysfunction. This isn’t hardware failure. It’s software. The regulatory system gets stuck in overdrive. Let me walk through the major contributing factors I see in practice. Autoimmune Conditions Chronic autoimmune inflammation creates a persistent state of immune activation that can sensitize mast cells over time. Patients with conditions like hypermobile Ehlers-Danlos syndrome show increased prevalence of inflammatory diseases and autoantibodies. MCAS has been reported alongside connective tissue disorders and dysautonomia, suggesting shared pathophysiology rooted in immune dysregulation. Mold Exposure and Mycotoxins Water-damaged buildings harbor toxigenic molds like Stachybotrys, Aspergillus, and Penicillium. The mycotoxins they produce—ochratoxin A, aflatoxins, trichothecenes—are potent immune disruptors. They directly activate mast cells, disrupt mitochondrial function, and promote systemic inflammation. I’ve seen patients whose MCAS symptoms dramatically improved once they addressed their mold exposure—and others who couldn’t make progress until they did. Lyme Disease and Co-infections Research has confirmed that Borrelia burgdorferi spirochetes—the bacteria causing Lyme disease—directly trigger mast cell degranulation. A 1999 study in Infection and Immunity showed that mast cells exposed to B. burgdorferi release proinflammatory cytokines like TNF-alpha. More recent work demonstrated that OspC, a surface protein involved in early Borrelia transmission, induces mast cell degranulation. In my practice, about half of patients with tickborne infections also experience MCAS symptoms. The overlap is striking—and treating the mast cell component often clarifies which symptoms are truly from the underlying infection. Long COVID Perhaps the most compelling evidence for the “immune derangement” model comes from Long COVID research. A landmark 2021 study by Weinstock and colleagues compared Long COVID patients with established MCAS patients and healthy controls. The finding was remarkable: before COVID infection, Long COVID patients had virtually identical symptom profiles to healthy controls. After infection, their profiles were virtually identical to MCAS patients. The researchers concluded that increased mast cell activation induced by SARS-CoV-2 may underlie part of Long COVID’s pathophysiology. This validates what integrative practitioners have been observing clinically—and suggests therapeutic approaches that actually help. Long COVID involves multiple immune disruptions: T-cell depletion, innate immune hyperactivity, loss of naive T and B cells, and elevated pro-inflammatory cytokines. This pattern of immune chaos—rather than a targeted response—is exactly what I mean by “derangement.” Why This Matters for Treatment Understanding MCAS as an immune derangement syndrome with multiple contributing factors fundamentally changes how we approach treatment. Mast cell stabilizers help. Antihistamines provide symptomatic relief and can reduce flushing and anaphylactic episodes, especially combined with other medications like corticosteroids or prostaglandin inhibitors. But they’re not enough if we ignore what pushed the system over the edge in the first place. Real treatment means asking: what got you here? That means comprehensive evaluation for mold exposure, Lyme and co-infections, autoimmune conditions, and viral reactivation. It means accepting that patients may need multimodal strategies rather than single-target interventions. And it means using immunomodulators like low-dose naltrexone as part of a broader approach to restore immune regulation—not just suppress symptoms. One important note: acute MCAS episodes should be treated like anaphylaxis. If a patient is having a severe reaction, epinephrine comes first. We can address root causes once they’re stable. In my LDN Primer, I discuss how MCAS fits into a larger framework of complex chronic conditions where LDN serves as one critical component but cannot achieve remission alone. For these patients, LDN calms the immune system enough to make deeper treatment more successful and better tolerated—but we still have to address root causes. The Path Forward MCAS Integrative Medicine Functional Medicine I want to be honest about what we don’t know. The underlying mechanisms that lead to mast cell activation in MCAS patients aren’t fully understood. We need better biomarkers, better diagnostic criteria, and more research into why some patients tip into chronic dysfunction while others recover. But we know enough to help patients now. We know MCAS rarely exists in isolation. We know chronic infections, toxic exposures, and autoimmunity can all sensitize mast cells. And we know that addressing these root causes—rather than just stabilizing mast cells—offers the best hope for meaningful, lasting improvement. MCAS isn’t a diagnosis. It’s a destination. And the clinical question that matters most is: what got you here? References 1. Zaghmout T, Maclachlan L, Bedi N, Gülen T. Low prevalence of idiopathic mast cell activation syndrome among 703 patients with suspected mast cell disorders. J Allergy Clin Immunol Pract . 2024;12(3):753-761. 2. Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis . 2021;112:217-226. 3. Talkington J, Nickell SP. Borrelia burgdorferi spirochetes induce mast cell activation and cytokine release. Infect Immun . 1999;67(3):1107-1115. 4. Bernard Q, Gadería-Fuentes M, Rath E, et al. Interaction of primary mast cells with Borrelia burgdorferi (sensu stricto): role in transmission and dissemination. Parasit Vectors . 2017;10(1):313. 5. Sumantri S, Rengganis I. Immunological dysfunction and mast cell activation syndrome in long COVID. Asia Pac Allergy . 2023;13(1):50-53. 6. Castells M, Giannetti MP, Hamilton MJ, et al. Mast cell activation syndrome: Current understanding and research needs. J Allergy Clin Immunol . 2024;154(2):255-263. 7. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis . 2020;100:327-332. About the Author Yoon Hang Kim, MD, MPH is a board-certified preventive medicine physician and graduate of the University of Arizona Integrative Medicine Fellowship. He has been prescribing low-dose naltrexone for over two decades and has presented at multiple LDN Research Trust conferences. Dr. Kim practices telemedicine through Direct Integrative Care, serving patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. www.directintegrativecare.com

What Actually Works, What Doesn't, and How to Navigate the Hype Role of Curcumin in Integrative & Functional Medicine Practice Yoon Hang Kim, MD, MPH, FAAMA Board Certified, Preventive Medicine | Integrative Medicine Fellowship, University of Arizona www.directintegrativecare.com I'll never forget Miss Dorothy. She was one of my first integrative medicine patients.  She was frustrated and skeptical. She'd tried everything for her post-surgical back pain due to a motor vehicle accident—physical therapy, steroid injections, and even surgery. The anti-inflammatory protocol, integrative pain modalities including PENS acupuncture, and neurostimulation provided her with enough relief.  Curcumin was the backbone of her anti-inflammatory supplements. That conversation captures everything I want to share with you today. After 20+ years of prescribing curcumin in clinical practice, I've seen remarkable successes and frustrating failures. The difference usually comes down to understanding a few key things that most articles gloss over. Let's Start with Some Honest Numbers Here's something you won't read in most supplement marketing: roughly one-third of my patients don't respond meaningfully to curcumin. That's not a failure of the compound—it's biology. People vary. Their gut microbiomes differ. Their inflammatory pathways aren't identical. Some folks metabolize curcumin so fast it never reaches therapeutic levels. But flip that around: about two-thirds do  respond, often dramatically. Published studies show response rates between 57-65% for chronic pain conditions. Those are actually pretty good odds for a natural compound with minimal side effects. The key is setting realistic expectations and understanding who's most likely to benefit. How Curcumin Actually Works (Without the Jargon) Your body has a kind of "inflammation thermostat" called NF-κB. When this gets stuck in the "on" position—which happens with chronic conditions like arthritis, autoimmune disease, or persistent pain—your tissues stay inflamed even when there's no acute injury. Curcumin essentially helps reset that thermostat. It blocks NF-κB from entering cell nuclei and turning on inflammatory genes. Less NF-κB activation means less COX-2 (the enzyme that NSAIDs target), fewer inflammatory cytokines like TNF-α and IL-6, and reduced production of prostaglandins. Think of it this way: NSAIDs like ibuprofen work downstream, mopping up inflammatory chemicals after they're made. Curcumin works upstream, reducing production of those chemicals in the first place. That's why it can take longer to feel effects—you're not just blocking symptoms, you're changing the underlying process. There's also growing evidence that curcumin has antioxidant effects, supports healthy aging at the cellular level, and may even benefit mood and cognitive function. But honestly, the anti-inflammatory action is where the strongest clinical evidence lies. The Absorption Problem (And Why Your Turmeric Might Be Useless) Here's the frustrating reality: curcumin is notoriously hard to absorb. It's fat-soluble, poorly water-soluble, gets rapidly metabolized by your liver, and most of what you swallow passes straight through you. How bad is it? In one study, people took 12 grams of curcumin—that's a massive  dose—and barely detectable amounts showed up in their blood. The compound has a half-life of about 10 minutes in the bloodstream. It's there, then it's gone. This is why formulation matters enormously. Not all curcumin products are created equal—not even close. What the Different Formulations Actually Do I'll break this down practically, because I know you're probably wondering what to actually buy: Curcumin + Black Pepper (Piperine): This is the classic combo. Piperine inhibits enzymes in your liver and gut that normally break down curcumin, boosting absorption about 20-fold. It's affordable and widely available. The catch: piperine also affects how your body processes many medications. If you're on blood thinners, certain heart drugs, or anything metabolized by liver enzymes, this can be a problem. I avoid it in patients with complex medication regimens. Meriva (Phospholipid Complex): Curcumin wrapped in phosphatidylcholine—basically, fats that help it cross cell membranes. About 4x better absorption than plain curcumin. This one has the most clinical trial data specifically for joint health. It's my go-to for osteoarthritis patients who can't use piperine. Theracurmin (Micronized): They grind the curcumin into microscopic particles using a gum-based process. Roughly 27x better absorption. Good option, though pricier. BCM-95 / Curcugreen: Combines curcumin with turmeric's natural essential oils. About 7x improved absorption. A solid middle-ground option. NovaSOL (Micellar): Liquid micelle technology claiming up to 185x better absorption. Those numbers sound impressive, but here's the thing: even with dramatic absorption improvements, blood levels still stay well below what we see working in lab studies. This has led some researchers to wonder if blood levels are even the right thing to measure—maybe the effects happen in the gut, or via metabolites we're not tracking. Longvida: Uses solid lipid particle technology. Particularly interesting for brain-related applications since it may cross the blood-brain barrier better than other forms. Formulation Absorption Boost vs. Plain Curcumin Piperine (black pepper) ~20x (but watch drug interactions) BCM-95 / Curcugreen ~7x Meriva (phospholipid) ~4x (best joint data) Theracurmin (micronized) ~27x NovaSOL (micellar) Up to 185x (highest numbers) Longvida ~65x (good for brain) My practical advice: Don't obsess over the absorption numbers. Pick a quality formulation that fits your situation (medication interactions, budget, specific condition) and give it a fair trial of 8-12 weeks. The Safety Stuff You Actually Need to Know Curcumin has a remarkably good safety profile. Studies using up to 12 grams daily haven't shown serious toxicity. Most people tolerate it well. But "generally safe" doesn't mean "safe for everyone in every situation." Here's where I want you to pay attention: If You're on Blood Thinners—Please Read This Curcumin has mild blood-thinning effects of its own. Usually not a problem. But combine it with warfarin, aspirin, Plavix, or other anticoagulants, and you're stacking effects. I've seen case reports of people's INR (clotting measure) shooting up to dangerous levels after adding turmeric supplements. If you're on blood thinners and want to try curcumin, please work with your doctor and monitor your labs more frequently during the transition. And stop curcumin at least two weeks before any surgery. Diabetes Medications Curcumin can enhance the blood sugar-lowering effects of diabetes drugs. That's potentially helpful—but it also means your current doses might become too strong. One study found that adding curcumin to glyburide kept blood sugars significantly lower for 24 hours. Great news for diabetes management, but it requires dose adjustments, not just piling supplements on top of existing medications. Other Considerations Gallbladder problems: Turmeric stimulates bile production. If you have gallstones or bile duct issues, this can cause pain or complications. Skip the curcumin. Iron deficiency: Curcumin can reduce iron absorption. If you're anemic or prone to low iron (common in women with heavy periods or anyone with chronic disease), be aware of this. Pregnancy: Culinary amounts in food are fine. Concentrated supplements? We don't have good safety data, and there's theoretical concern about uterine stimulation. I advise pregnant patients to avoid supplemental doses. Acid reflux medications: Curcumin may increase stomach acid, potentially counteracting PPIs like omeprazole. Some patients notice more heartburn. The Dirty Secret About Supplement Quality I wish I didn't have to write this section, but the curcumin supplement market has serious problems. One company tested 23 turmeric products from Amazon. The results? Twelve failed—for containing synthetic curcumin (not disclosed), heavy metal contamination, wrong potency, or using gelatin capsules instead of the advertised vegetarian ones. That's more than half. Heavy metals are a particular concern. Some products had lead levels 20 times higher than quality brands and exceeded California's safety limits. Two products had cadmium above 100 parts per billion. You're taking something to improve your health and potentially poisoning yourself instead. Why does this happen? Some of it is intentional fraud—adding synthetic curcumin (cheaper than natural) or lead chromate (makes the powder look more vibrant yellow). Some is just poor quality control from manufacturers cutting corners. How to Protect Yourself Look for third-party testing. USP, NSF International, and ConsumerLab.com all independently verify supplement contents. A seal from one of these organizations means someone actually checked what's in the bottle. But verify the certification is real—some companies fake these logos. Check the certifying organization's website. Be suspicious of bargain prices. Quality curcumin extraction isn't cheap. If a product costs dramatically less than competitors, ask yourself why. There's usually a reason. Check the color. Natural turmeric has a deep orange-yellow color. If powder looks artificially bright or neon yellow, that's a red flag for added colorants. Stick with established brands. Companies that have been around for years, have reputations to protect, and publish their testing protocols are generally safer bets than unknown Amazon sellers. What Does the Research Actually Show? Let me cut through the noise and tell you where the evidence is strongest. Osteoarthritis: Solid Evidence Multiple meta-analyses—studies that pool data from many trials—show curcumin reduces pain and improves function in knee osteoarthritis. The effects are comparable to NSAIDs for some patients, without the stomach and cardiovascular risks of long-term NSAID use. Remember Mrs. Patterson from the beginning? After switching her to a quality phospholipid formulation, she noticed improvement by week six. Not a miracle cure—she still has arthritis—but enough reduction in pain and stiffness that she's gardening again and postponed that surgery conversation. Rheumatoid Arthritis: Promising Studies show curcumin can reduce inflammatory markers (ESR, CRP), disease activity scores, and pain levels in RA patients. It's not a replacement for disease-modifying drugs, but it may help as an add-on therapy. I use it frequently in my RA patients alongside their conventional medications. Inflammatory Bowel Disease: Interesting Early Data Several studies suggest curcumin helps maintain remission in ulcerative colitis when added to standard therapy. The research on Crohn's disease is less clear. This is an area where working closely with a gastroenterologist makes sense. Other Conditions: Mixed or Early You'll see claims about curcumin for depression, Alzheimer's, cancer prevention, metabolic syndrome, and dozens of other conditions. Some have intriguing preliminary data. But I try to be honest with patients: for most of these applications, we're still in the "promising but not proven" stage. The strongest evidence remains for inflammatory joint conditions. Who Should Consider Curcumin? Based on the evidence and my clinical experience, these folks are most likely to benefit: Older Adults with Joint Issues If you're over 60 with osteoarthritis and can't tolerate NSAIDs (or worry about their long-term effects), curcumin is worth trying. Studies specifically in this population show benefits for muscle strength and physical function, not just pain relief. Athletes Dealing with Recovery Issues Research shows curcumin can help manage exercise-induced inflammation and muscle soreness. If you're training hard and struggling with recovery, an 8-week trial might be illuminating. One study found 500mg daily significantly reduced markers of muscle damage in active women. People with Chronic Low-Grade Inflammation If your CRP is consistently elevated, if you have metabolic syndrome, or if you're dealing with autoimmune-related inflammation, curcumin's multi-pathway approach might help where single-target drugs haven't fully controlled things. So What Should You Actually Do? If you've read this far, you're probably wondering: "Okay, but what would you  recommend?" Here's my practical approach: Start with your medication list. If you're on blood thinners, diabetes drugs, or multiple medications metabolized by the liver, talk to your doctor first. Seriously. Drug interactions matter. Choose the right formulation. For most people with joint issues and no drug interaction concerns, Meriva (phospholipid) or C3 Complex with BioPerine work well. If you need to avoid piperine, go with Meriva or Theracurmin. Buy quality. Look for third-party tested products from established brands. Yes, they cost more. Consider it insurance against wasting money on products that don't work—or worse, contain contaminants. Give it time. Unlike ibuprofen, curcumin doesn't work in 30 minutes. Most studies showing benefit run 8-12 weeks. Commit to a fair trial before deciding if it helps. Track your response. Keep notes on your pain levels, function, and any side effects. If you're not noticing benefit by 12 weeks, curcumin might not be your answer—and that's okay. About a third of people are in that boat. Don't treat it as a magic bullet. Curcumin works best as part of a comprehensive approach—good nutrition, appropriate exercise, stress management, and whatever other treatments your specific condition requires. The Bottom Line Curcumin isn't the miracle cure that supplement marketing sometimes suggests. But it's also not useless hype. The science supports real benefits for inflammatory conditions, particularly osteoarthritis and rheumatoid arthritis. Two-thirds of patients in studies get meaningful relief. The side effect profile is genuinely good. And for people who can't tolerate conventional anti-inflammatory drugs, it offers a legitimate alternative. The caveats are real too: bioavailability requires the right formulation, drug interactions need attention, and product quality varies wildly. Navigating these issues takes some effort. But when you get it right—right patient, right product, right expectations—curcumin can be a valuable part of the healing toolkit. Mrs. Patterson would tell you the same thing, between trips to her garden. Selected References Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health. Foods. 2017;6(10):92. Zeng L, et al. Efficacy and safety of curcumin and Curcuma longa extract in the treatment of arthritis. Front Immunol. 2022;13:891822. Zhao J, et al. Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis. J Ethnopharmacol. 2024;321:117493. Schiborr C, et al. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans. Mol Nutr Food Res. 2014;58(3):516-527. Kou H, et al. Effect of curcumin on rheumatoid arthritis: a systematic review and meta-analysis. Front Immunol. 2023;14:1121655. Shoba G, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-356. Buhrmann C, et al. Curcumin Modulates Nuclear Factor κB-mediated Inflammation in Human Tenocytes. J Biol Chem. 2011;286(32):28556-28566. NOW Foods. Analysis of turmeric/curcumin products sold on Amazon. 2021. Disclosure: I have no financial relationships with any curcumin supplement manufacturers. This article reflects my clinical experience and interpretation of the evidence—not medical advice for your specific situation. Always work with your healthcare provider before starting new supplements, especially if you take medications. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional: www.yoonhangkim.com  | Clinical: www.directintegrativecare.com About Dr. Kim's Telemedicine Practice At www.directintegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality. Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com

By Yoon Hang Kim, MD, MPH If you've spent any time researching supplements for cardiovascular health or exercise performance, you've probably come across nitric oxide boosters. They're everywhere—from beetroot powders at your local health food store to amino acid blends marketed to athletes. But here's what I tell my patients: not all nitric oxide supplements work the same way, and choosing the right one depends entirely on what you're trying to accomplish. Let me break down what we actually know about these supplements and help you figure out which approach might make sense for you. Why Nitric Oxide Matters for Your Health Nitric oxide is one of those molecules that quietly runs the show behind the scenes. It helps your blood vessels relax and dilate, which improves circulation throughout your body. It also plays a role in immune function, brain signaling, and how your cells produce energy. Here's the catch: your body makes less nitric oxide as you get older. And if you're dealing with conditions like high blood pressure, diabetes, or heart disease, your nitric oxide production may already be compromised. This decline has sparked a lot of interest in finding ways to boost nitric oxide levels through diet and supplementation—a approach that fits naturally within integrative and functional medicine, where we focus on supporting the body's own healing mechanisms rather than just managing symptoms. The Two Pathways: Understanding How Your Body Makes Nitric Oxide Before choosing a supplement, it helps to understand that your body produces nitric oxide through two different routes. The L-Arginine Pathway:  Your cells use an enzyme called nitric oxide synthase (NOS) to convert the amino acid L-arginine into nitric oxide. This is your body's primary production method. The Nitrate-Nitrite Pathway:  When you eat nitrate-rich foods like beets and leafy greens, bacteria in your mouth convert those nitrates into nitrites, which your body then transforms into nitric oxide. This backup pathway becomes especially important when the primary pathway isn't working well. Why does this matter? Because different supplements target different pathways—and what works best for you may depend on which pathway needs the most support. L-Arginine and L-Citrulline: The Amino Acid Approach L-arginine seems like the obvious choice for boosting nitric oxide since your body uses it directly. But here's something that surprises many of my patients: when you take L-arginine by mouth, most of it gets broken down in your liver before it ever reaches your bloodstream. L-citrulline, on the other hand, takes a different route. It bypasses your liver entirely and gets converted to L-arginine in your kidneys. This metabolic quirk means L-citrulline actually raises your blood arginine levels more effectively than taking arginine itself. What the Research Shows A well-designed study comparing these two amino acids found that seven days of L-citrulline supplementation (6 grams daily) did a better job of increasing nitric oxide markers than an equivalent dose of L-arginine. The citrulline group also saw improvements in blood pressure and exercise performance—benefits that didn't show up with arginine alone. Even more interesting: combining L-citrulline and L-arginine at lower doses (about 1.2 grams of each) appears to work synergistically. Research on collegiate soccer players found this combination improved cycling performance and post-exercise nitric oxide levels. The reason? Citrulline doesn't just turn into arginine—it also blocks the enzyme that breaks arginine down. So when you take them together, the citrulline protects the arginine from being destroyed before your body can use it. Beetroot and Dietary Nitrates: The Vegetable-Based Strategy If the amino acid pathway in your body isn't working optimally—which happens with aging, diabetes, and cardiovascular disease—beetroot and other nitrate-rich foods offer an alternative route to boosting nitric oxide. This is where functional medicine's emphasis on food as medicine really shines. Rather than viewing beets as just another vegetable, we can understand them as a targeted intervention that bypasses a dysfunctional pathway. Blood Pressure Benefits The evidence for beetroot juice and blood pressure is probably the strongest we have for any nitric oxide supplement. Multiple studies have found that beetroot juice reliably lowers both systolic and diastolic blood pressure, with the most consistent benefits appearing in people who already have elevated blood pressure. A systematic review from 2022 confirmed these findings, showing meaningful blood pressure reductions in adults with hypertension after beetroot juice supplementation. Beyond Blood Pressure Recent research has also shown benefits for vascular function that go beyond simple blood pressure readings. A 2024 study in postmenopausal women—a group with elevated cardiovascular risk after estrogen levels decline—found that one week of dietary nitrate supplementation significantly improved how their blood vessels function. This kind of finding is particularly relevant for women navigating the cardiovascular changes that come with menopause. So Which Supplement Should You Choose? Here's my honest answer: it depends on your goals. For blood pressure and cardiovascular support:  Beetroot juice or standardized nitrate supplements have the most consistent evidence. Look for products providing about 300-500 mg of dietary nitrate—roughly equivalent to 500 mL of beetroot juice. The benefits are clearest in people who already have elevated blood pressure or signs of blood vessel dysfunction. For exercise performance and physical energy:  L-citrulline, either alone (3-6 grams daily) or combined with L-arginine (1-2 grams of each), has better support for improving exercise capacity and oxygen utilization. These benefits are most pronounced in recreational exercisers; elite athletes may see smaller improvements. For impaired endothelial function:  When the cells lining your blood vessels aren't working well—which happens with aging, diabetes, and established heart disease—combining both approaches makes physiological sense. Using L-citrulline/L-arginine alongside dietary nitrates addresses both pathways simultaneously. I should note that we don't yet have large clinical trials testing this combined approach. The recommendation comes from understanding the mechanisms rather than definitive outcome data. What About Those Proprietary Blends? Several companies sell specialized nitric oxide formulas combining various ingredients. Some research suggests these products can increase nitric oxide markers in saliva or blood. However, I approach these products with some caution. Many of the studies are industry-funded, and the evidence often stops at biomarker changes rather than demonstrating actual health improvements. That doesn't mean they're ineffective—just that the evidence is less mature. Safety Considerations and Practical Tips These supplements are generally well-tolerated, but a few things are worth knowing: L-Arginine:  High doses can cause GI upset. More importantly, some research has raised concerns about L-arginine supplementation in people who've recently had a heart attack. If you have established cardiovascular disease, definitely work with your physician. Dietary Nitrates:  The main practical consideration is mouthwash. Chlorhexidine-containing mouthwashes kill the oral bacteria that convert nitrate to nitrite, essentially blocking this pathway. If you're using beetroot supplements, skip the antibacterial mouthwash. All Nitric Oxide Supplements:  These can add to the blood pressure-lowering effects of antihypertensive medications or drugs like Viagra. Blood pressure monitoring during the initial period is wise if you're on vasoactive medications. The Functional Medicine Perspective In functional medicine, we think about supplements differently than conventional medicine often does. Rather than asking "what pill treats this symptom," we ask "what's the underlying dysfunction and how can we support the body's own repair mechanisms?" For nitric oxide, that means: Assessing the whole person  rather than just prescribing a supplement Considering dietary foundations first —leafy greens and beets should be part of a cardiovascular-supportive diet regardless of supplementation Choosing supplements based on the specific pathway  that needs support Monitoring response  and adjusting the approach based on what's working The goal isn't to take a supplement forever. It's to support healing while addressing root causes—whether that's improving diet, managing blood sugar, optimizing sleep, or reducing inflammation. Starting with Beetroot Powder: A Practical Guide For patients new to nitric oxide supplementation, I often recommend starting with beetroot powder as an accessible entry point. Here's a reasonable approach: Starting dose:  1-2 teaspoons daily, mixed in water, juice, or a smoothie Timing:  Many people take it in the morning or 2-3 hours before exercise What to watch for:  Blood pressure effects (especially if you're on medications), and the completely harmless but sometimes alarming red color it can give to urine and stool Quality matters:  Look for organic products from reputable companies. The nitrate content can vary significantly between products. And as always, if you're taking medications or managing chronic conditions, work with a physician who understands both your health situation and how these supplements interact with your treatment plan. The Bottom Line Nitric oxide supplementation makes physiological sense for many people, particularly those dealing with cardiovascular concerns or looking to support exercise performance as they age. But there's no universal "best" supplement. The choice between L-citrulline, beetroot, or a combined approach should be based on your specific goals, health status, and which nitric oxide pathway needs the most support. The research continues to evolve, and I suspect we'll have more refined recommendations in the coming years. For now, the evidence supports a thoughtful, individualized approach—which is really what good integrative medicine should always be about. References Bailey SJ, Blackwell JR, Lord T, et al. L-citrulline supplementation improves O2 uptake kinetics and high-intensity exercise performance in humans. Journal of Applied Physiology . 2015;119(4):385-395. Jones AM. Dietary nitric oxide precursors and exercise performance. Sports Science Exchange . 2016;29(156):1-6. Kiani AK, Bonetti G, Medori MC, et al. Dietary supplements for improving nitric-oxide synthesis. Journal of Preventive Medicine and Hygiene . 2022;63(2 Suppl 3):E239-E245. Morita M, Hayashi T, Ochiai M, et al. Oral supplementation with a combination of L-citrulline and L-arginine rapidly increases plasma L-arginine concentration and enhances NO bioavailability. Biochemical and Biophysical Research Communications . 2014;454(1):53-57. Proctor S, Biggerstaff K, Pugh J. Seven-day dietary nitrate supplementation clinically significantly improves basal macrovascular function in postmenopausal women. Frontiers in Nutrition . 2024;11:1359671. Suzuki I, Sakuraba K, Horiike T, et al. A combination of oral L-citrulline and L-arginine improved 10-min full-power cycling test performance in male collegiate soccer players. European Journal of Applied Physiology . 2019;119(5):1075-1084. Wong SA, Rowlands D, Chan J, Bailey TG. Effect of dietary supplements which upregulate nitric oxide on walking and quality of life in patients with peripheral artery disease. Biomedicines . 2023;11(7):1859. Zamani H, de Joode M, Hossein G, et al. Nitrate derived from beetroot juice lowers blood pressure in patients with arterial hypertension. Frontiers in Nutrition . 2022;9:823039. Dr. Yoon Hang Kim is a board-certified preventive medicine physician and integrative medicine specialist. He practices telemedicine through Direct Integrative Care, serving patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. www.directintegrativecare.com

Yoon Hang Kim MD Complex Regional Pain Syndrome (CRPS) remains one of the most challenging chronic pain conditions we encounter. Patients typically present with severe, disproportionate pain following injury or surgery, often accompanied by sensory disturbances, temperature and color changes, swelling, and motor dysfunction. The underlying pathophysiology involves both peripheral and central sensitization, with sympathetic nervous system dysregulation and neuroinflammation playing key roles. Management requires a multidisciplinary approach combining medications, physical rehabilitation, psychological support, and sometimes interventional procedures. Two modalities that deserve attention for refractory cases are radiofrequency ablation (RFA) and low-dose naltrexone (LDN) — each targeting different aspects of the condition's complex pathophysiology. Radiofrequency Ablation RFA uses radiofrequency energy delivered through a needle electrode to disrupt nerve conduction. For CRPS, the typical targets are sympathetic ganglia: the stellate ganglion for upper extremity involvement, or the lumbar sympathetic chain for lower extremity cases. Continuous RFA produces thermal neurolysis, while pulsed RFA (PRF) offers neuromodulation without significant tissue destruction. The evidence base includes case reports, retrospective series, and limited comparative studies showing prolonged pain reduction — sometimes lasting months to years — particularly in patients with sympathetically maintained pain. Systematic reviews suggest moderate evidence, though larger randomized trials are still needed. Potential complications  include temporary pain flare, numbness, paresthesia, bruising, and infection. Stellate ganglion procedures carry risk of Horner syndrome. Rare but serious complications include vascular injury, pneumothorax, and paradoxically, worsening or new-onset CRPS. Pulsed RFA generally carries lower risk than continuous thermal ablation. Low-Dose Naltrexone LDN — typically dosed at 1–4.5 mg daily — represents an off-label use of the opioid antagonist naltrexone. At these low doses, the mechanism shifts from opioid receptor blockade to modulation of Toll-like receptor 4 (TLR4) on glial cells. This attenuates microglial activation and reduces the neuroinflammatory cascade that drives central sensitization. The CRPS-specific evidence comes primarily from case reports and retrospective analyses. The landmark 2013 report by Chopra and Cooper documented remission of prominent CRPS symptoms — including dystonic spasms, fixed dystonia, allodynia, and vasomotor changes — in patients who had failed conventional therapies. More recent retrospective data suggests higher response rates in patients with neuropathic pain profiles, including CRPS. That said, high-quality randomized controlled trials specifically in CRPS remain lacking, and broader chronic pain reviews show variable results. Side effects  are generally mild and often transient: vivid dreams, drowsiness, dizziness, nausea, headache, and insomnia. These frequently resolve with continued use or dose adjustment. Serious adverse events are rare, and tolerability is high. Comparing the Two Approaches No head-to-head trials compare RFA and LDN in CRPS, so we're left extrapolating from their different mechanisms and available evidence. RFA  targets sympathetically mediated pain directly. For the right patient — one with a positive diagnostic sympathetic block — it can provide substantial, relatively rapid relief. However, it's invasive, requires specialized expertise, and carries procedural risks. LDN  works systemically, addressing the glial-driven neuroinflammation and central sensitization that underlie many CRPS cases. It's non-invasive, well-tolerated, and inexpensive, but benefits typically develop gradually over weeks to months. From a safety standpoint, LDN has clear advantages: oral administration, minimal adverse effects, and very low discontinuation rates. RFA, while generally safe when performed under imaging guidance, involves inherent procedural risks. Practical Considerations Both interventions are typically reserved for patients who haven't responded adequately to first-line measures. Diagnostic sympathetic blocks help identify RFA candidates, while LDN often requires a trial of several weeks to months before efficacy can be assessed. Patient selection should consider the predominant pain mechanism. Those with clear sympathetically maintained features may be better candidates for RFA, while patients with more central or inflammatory components may respond well to LDN. In practice, these aren't mutually exclusive — some patients benefit from both approaches as part of a comprehensive treatment plan. Larger randomized trials are needed to clarify optimal protocols, comparative effectiveness, and how to best identify responders to each modality. References Chopra P, Cooper MS. Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013;8(3):470-476. McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V. Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series. J Pain Res. 2023;16:1993-1998. Rupp A, et al. Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review. Pain Med. 2023;24(11):1270-1281. Vuka I, et al. Interventional radiofrequency treatment for the sympathetic nervous system: a review article. Pain Ther. 2021;10(1):19-34. Yang J, et al. The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: a systematic review. J Pain Res. 2023;16:1017-1023.

A Clinical Perspective from Two Decades of LDN Practice Yoon Hang Kim, MD, MPH, FAAMA Direct Integrative Care & Functional Medicine via Telemedicine Serving IA, IL, MO, GA, FL, TX www.directintegrativecare.com Introduction Long COVID, formally known as post-acute sequelae of SARS-CoV-2 infection (PASC), continues to challenge healthcare systems globally. Millions of patients experience persistent symptoms including fatigue, cognitive impairment, pain, and sleep disturbances that can persist for months or years after initial infection. As a physician who has prescribed low-dose naltrexone (LDN) for over two decades and presented at multiple LDN Research Trust conferences, I have witnessed firsthand how this therapy can benefit patients with complex chronic conditions. The emerging evidence for LDN in Long COVID represents a natural extension of its established applications in fibromyalgia, chronic fatigue syndrome, and autoimmune disorders. This article synthesizes current evidence, mechanisms, and clinical applications of LDN for Long COVID, drawing from both published research and clinical experience. While LDN remains an off-label intervention, the growing body of preliminary evidence warrants serious consideration by clinicians seeking options for their patients with post-COVID symptoms. Understanding Low-Dose Naltrexone Naltrexone is an opioid antagonist conventionally administered at doses exceeding 50 mg for managing opioid and alcohol dependence. However, at low doses (typically 0.5–4.5 mg), LDN operates through fundamentally different pathways. Rather than serving as a direct opioid blocker, LDN functions primarily as an anti-inflammatory agent and immune modulator (Younger et al., 2014). This mechanistic shift is crucial to understanding LDN’s therapeutic potential. At low doses, naltrexone acts as a TLR4 antagonist, mitigating microglial activation and reducing neuroinflammation. Additionally, transient opioid receptor blockade triggers a rebound increase in endogenous endorphin production, which modulates immune function (Toljan & Vrooman, 2018). These mechanisms make LDN particularly relevant for conditions characterized by neuroinflammation and immune dysregulation—hallmarks of Long COVID. LDN Functional Medicine Perspective Long Covid - Current Research Status Observational Studies and Pilot Data Multiple observational studies have reported improvements in fatigue, pain, sleep, cognition, and daily functioning after one to three months of LDN therapy, with response rates of 50–60%. A landmark study from Dublin tracked 38 Long COVID patients and documented gains in energy levels, pain reduction, concentration, sleep quality, and overall recovery perception after two months of treatment (O’Kelly et al., 2022). A 2022 pilot study involving 36 patients with post-COVID fatigue demonstrated enhanced fatigue scores and quality of life when LDN (4.5 mg/day) was combined with transdermal NAD⁺ (Campagnolo et al., 2024). While this study lacked a control group, the magnitude of improvement was notable. A 2025 systematic review reinforced these findings, suggesting LDN improves fatigue, cognition, sleep, pain, and functioning, with 73.9% of patients reporting positive responses. A November 2025 meta-analysis further demonstrated statistically significant reductions in fatigue, brain fog, and headaches (Darkoh et al., 2025). Patient-Reported Outcomes A landmark 2025 study published in Proceedings of the National Academy of Sciences  analyzed patient-reported outcomes from over 3,900 individuals with ME/CFS and Long COVID (Eckey et al., 2025). LDN achieved a net approval score of 49.4%, with patients reporting improvements in fatigue (41.5%), post-exertional malaise (33.2%), and brain fog (42.3%). Notably, LDN was among the most effective treatments with one of the lowest instances of side effects. Ongoing Clinical Trials Several randomized controlled trials are advancing to clarify LDN’s efficacy. The British Columbia trial (NCT05430152), a double-blind, placebo-controlled study assessing LDN’s impact on fatigue and inflammatory markers in post-COVID fatigue syndrome, has completed enrollment (Naik et al., 2024). The NIH RECOVER-TLC pediatric/young adult LDN trial targets fatigue reduction in ages 6–25. The LIFT trial (NCT06366724) at Brigham and Women’s Hospital combines LDN with pyridostigmine for ME/CFS and Long COVID with orthostatic intolerance. Proposed Mechanisms of Action LDN’s potential in Long COVID stems from several hypothesized mechanisms: Glial Modulation and Neuroinflammation Reduction: LDN acts as a TLR4 antagonist, mitigating microglial activation in the brain. This mechanism may address the persistent neuroinflammation contributing to fatigue, pain, and cognitive dysfunction in Long COVID (Younger et al., 2014). Restoration of Ion Channel Function: Groundbreaking 2025 research from Griffith University demonstrated that LDN (3–4.5 mg/day) restores TRPM3 ion channel function in natural killer cells from Long COVID patients. This finding addresses immune dysregulation—a proposed biomarker in Long COVID—and correlates with quality-of-life improvements (Sasso et al., 2025). Endorphin Upregulation: Transient opioid receptor blockade boosts endogenous endorphin production, modulating immune function and pain perception—mechanisms paralleling those observed in ME/CFS and fibromyalgia. Clinical Approach: Lessons from Two Decades of Practice Drawing from my experience prescribing LDN across conditions including fibromyalgia, autoimmune disorders, and chronic pain, I have observed that approximately one-third of patients do not respond to standard LDN protocols. This clinical reality has shaped my approach to Long COVID. Assessing Endorphin Reserve Before initiating LDN, I assess each patient’s endorphin reserve by evaluating functional capacity. Key questions include: How long have they been symptomatic? Do they achieve restorative sleep? What is their baseline energy? How quickly do they recover from setbacks? Patients with severely depleted reserves require different dosing strategies than those with moderate illness. Dosing Strategies Standard protocols typically initiate oral LDN at 0.5–1.5 mg nightly, titrating to 3–4.5 mg/day over weeks, with treatment durations of 2–6+ months. However, for severely ill patients or those with low functional capacity, I recommend starting at microgram doses (ultra-low-dose naltrexone) and titrating very slowly—sometimes over months rather than weeks. The LDN Research Trust recognizes three dosing categories: ultra-low dose (microgram dosing), very-low dose (0.1–0.5 mg daily), and low dose (1–4.5 mg, sometimes up to 10 mg). Safety Profile LDN demonstrates a favorable safety profile with low discontinuation rates across chronic conditions. Common initial side effects include vivid dreams, insomnia, nausea, dizziness, fatigue, and mood alterations—typically resolving with dose adjustments. In the Dublin study, only 5.3% of patients discontinued due to adverse effects (O’Kelly et al., 2022). Important contraindications include concurrent opioid use, and LDN lacks formal guideline endorsement for Long COVID pending additional RCT data. Clinical Summary Common Dose: 0.5–4.5 mg daily (titrated slowly over weeks) Primary Mechanisms: TLR4 antagonism, glial modulation, TRPM3 restoration, endorphin upregulation Symptoms Targeted: Fatigue, brain fog, chronic pain, sleep disturbances, post-exertional malaise Key Evidence: Multiple pilot studies positive; RCTs in progress (NCT05430152, NCT06366724) Regulatory Status: Off-label; not FDA-approved specifically for Long COVID Limitations of Current Evidence Despite promising signals, current evidence is constrained by small sample sizes (typically <100 participants), lack of randomization in observational studies, and potential biases including spontaneous recovery. Phenotypic heterogeneity in Long COVID, variable infection-to-treatment intervals, and concurrent therapies limit generalizability. Systematic reviews appropriately classify LDN as “promising but low-certainty,” emphasizing the need for well-designed RCTs. Conclusion LDN represents a low-risk, accessible option for managing Long COVID symptoms, supported by growing preliminary evidence and compelling mechanistic insights. As randomized controlled trials mature in 2026, clearer efficacy data will emerge. In the meantime, clinicians should weigh individual patient profiles, assess endorphin reserve, titrate doses appropriately, and monitor for side effects. For patients struggling with persistent post-COVID symptoms and limited treatment options, LDN merits consideration as part of a comprehensive management strategy. As the quote often attributed to W. Edwards Deming reminds us: “A bad system will beat a good person every time.” For Long COVID patients navigating a healthcare system with limited approved treatments, LDN offers hope—not as a panacea, but as one promising tool in an evolving therapeutic landscape. Low-Dose Naltrexone: An Emerging Treatment for Long COVID References Campagnolo, N., Johnston, S., Collatz, A., Staines, D., & Marshall-Gradisnik, S. (2024). Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain, Behavior, & Immunity – Health, 36 , 100733. https://doi.org/10.1016/j.bbih.2024.100733 Darkoh, A., Ngwa, A. D. K., Akinbile, A. G., Ogunleye, A. E., & Osondu, C. (2025). Does low-dose oral naltrexone alleviate symptoms of Long COVID? A systematic review and meta-analysis. COVID, 5 (12), 198. https://doi.org/10.3390/covid5120198 Eckey, M., Li, P., Morrison, B., Bergquist, J., Davis, R. W., & Xiao, W. (2025). Patient-reported treatment outcomes in ME/CFS and long COVID. Proceedings of the National Academy of Sciences, 122 (28), e2426874122. https://doi.org/10.1073/pnas.2426874122 Naik, H., Cooke, E., Boulter, T., Dyer, R., Bone, J. N., Tsai, M., Cristobal, J., McKay, R. J., Song, X., & Nacul, L. (2024). Low-dose naltrexone for post-COVID fatigue syndrome: A study protocol for a double-blind, randomised trial in British Columbia. BMJ Open, 14 (5), e085272. https://doi.org/10.1136/bmjopen-2024-085272 O’Kelly, B., Vidal, L., McHugh, T., Woo, J., Avramovic, G., & Lambert, J. S. (2022). Safety and efficacy of low dose naltrexone in a long covid cohort: An interventional pre-post study. Brain, Behavior, & Immunity – Health, 24 , 100485. https://doi.org/10.1016/j.bbih.2022.100485 Sasso, E. M., Eaton-Fitch, N., Smith, P., Muraki, K., & Marshall-Gradisnik, S. (2025). Low-dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients. Frontiers in Molecular Biosciences, 12 , 1582967. https://doi.org/10.3389/fmolb.2025.1582967 Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences, 6 (4), 82. https://doi.org/10.3390/medsci6040082 Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, 2018 , bcr2017221405. https://doi.org/10.1136/bcr-2017-221405 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451–459. https://doi.org/10.1007/s10067-014-2517-2 About the Author Yoon Hang Kim, MD, MPH, FAAMA is a board-certified preventive medicine physician with an integrative medicine fellowship from the University of Arizona. He has been prescribing LDN for over two decades and has presented at multiple LDN Research Trust conferences internationally. Dr. Kim established integrative oncology programs at Miami Cancer Institute and the University of Kansas Medical Center. He currently practices functional medicine via telemedicine through Direct Integrative Care ( www.directintegrativecare.com ), serving patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. He is the author of Low Dose Naltrexone Therapy: An Evidence-Based Review and Case Histories  and the LDN Primer clinical guide. Disclosure: The author reports no conflicts of interest. LDN is an off-label treatment and patients should consult with qualified healthcare providers before initiating therapy.

By Yoon Hang "John" Kim, MD, MPH About the Author:  Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Dr. Kim is a recognized expert in low-dose naltrexone (LDN) therapy, having authored three books and more than 20 articles on the subject. He founded and moderates the LDN Support Group with over 7,000 members and has presented at multiple LDN Research Trust conferences. His clinical practice, Direct Integrative Care, serves patients across multiple states with a focus on autoimmune conditions, chronic pain, and complex chronic illness. Low-Dose Naltrexone in the Management of Sjögren's Syndrome -LDN Sjogren Sjögren's syndrome is one of those conditions that can quietly steal quality of life. It's a systemic autoimmune disease that primarily attacks moisture-producing glands, leaving patients with chronically dry eyes and mouth—but often so much more. Fatigue, joint pain, brain fog, and involvement of various organ systems can make daily life a real struggle. Low-dose naltrexone (LDN) has emerged as a promising option for these patients. At doses typically ranging from 0.5 to 4.5 mg per day, LDN behaves very differently from standard-dose naltrexone (50–100 mg) used in addiction medicine. Instead of blocking opioid receptors around the clock, LDN creates a brief, transient blockade that actually upregulates  the body's endorphin system and modulates immune function. While the published evidence remains limited to case reports, what we're seeing clinically is encouraging. Understanding Sjögren's Syndrome Sjögren's syndrome is a chronic autoimmune disorder where the immune system mistakenly attacks the lacrimal (tear) and salivary glands. The hallmark symptoms—dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia)—are what most people think of, but that's often just the tip of the iceberg. Many patients experience what I call "non-classic" or systemic Sjögren's: debilitating fatigue, widespread joint and muscle pain, peripheral neuropathies, cognitive difficulties, and involvement of the lungs, kidneys, skin, or nervous system. Some patients have minimal sicca symptoms but profound systemic manifestations. This heterogeneity is important to recognize because treatment approaches may differ. The disease predominantly affects women (approximately 9:1 ratio compared to men) and typically presents between ages 40 and 60, though it can occur at any age. Diagnosis involves clinical evaluation, serological tests (anti-SSA/Ro and anti-SSB/La antibodies), and sometimes minor salivary gland biopsy. Standard treatments focus on symptom management—artificial tears, saliva substitutes, and immunosuppressive agents like hydroxychloroquine—but no cure exists, and many patients remain symptomatic despite conventional therapy. How Does Low-Dose Naltrexone Work? LDN's mechanism is fascinating and counterintuitive. By briefly blocking opioid receptors (typically for just a few hours when taken at bedtime), LDN triggers a compensatory upregulation of endogenous endorphin production and enhances receptor sensitivity. This creates a "rebound" effect that persists throughout the day. Perhaps more importantly for autoimmune conditions, LDN antagonizes Toll-like receptor 4 (TLR4) on microglia and macrophages. This reduces pro-inflammatory cytokine release and calms neuroinflammation—a mechanism that may explain why patients often report improvements in fatigue, pain, and brain fog. The safety profile is remarkably favorable. The most common side effects are vivid dreams or mild sleep disturbance, which typically resolve within the first few weeks or can be managed by adjusting the timing of the dose. LDN must be obtained from compounding pharmacies since it's not commercially available in low-dose formulations. What Does the Published Evidence Show? The published evidence for LDN in Sjögren's syndrome consists primarily of case reports, but the results are consistent and encouraging. Dr. Scott Zashin, a rheumatologist at UT Southwestern, published the initial case report in 2019 describing a 47-year-old woman with suspected Sjögren's who had failed standard therapy. After initiating LDN, she experienced significant clinical improvement with reduction of inflammatory markers. In a 2020 follow-up publication, Zashin reported two additional cases. A 66-year-old woman with documented Sjögren's who had discontinued hydroxychloroquine due to concerns about retinal toxicity experienced recurrence of joint pain and elevated inflammatory markers. After starting LDN at 1 mg and titrating to 2 mg daily, her pain resolved and her ESR and CRP normalized. A 24-year-old woman with documented Sjögren's presenting with chronic widespread pain, fatigue, headaches, and markedly elevated inflammatory markers (ESR 90 mm/h, CRP 14.2 mg/L) showed progressive improvement after LDN titration, ultimately achieving normal inflammatory markers at one-year follow-up on 8.5 mg daily. A 2023 review in the Mediterranean Journal of Rheumatology  by de Carvalho and Skare examined LDN across rheumatological conditions and concluded that while data is limited, LDN appears to be a promising and safe option for pain management in Sjögren's syndrome. Notably, the published cases consistently show improvement in systemic symptoms—pain, fatigue, and inflammatory markers—rather than the sicca symptoms themselves. This makes sense given LDN's immunomodulatory mechanisms. Comparing Treatment Approaches Feature Standard Treatment LDN ± Ketosis Primary Goal Manage dryness; suppress immune activity Modulate immune response; reduce inflammation; support metabolic health Best For Sicca symptoms; preventing organ damage Fatigue, chronic pain, brain fog, neuropathy Availability Standard pharmacies; often insurance-covered Compounded LDN (not typically covered); ketosis via dietary modification Evidence Level High (established standard of care) Low to moderate (case reports, clinical experience) LDN should be viewed as an adjunct therapy, not a replacement for appropriate rheumatological care. Patients with Sjögren's syndrome benefit from a team approach—rheumatology, ophthalmology, dentistry, and, when appropriate, integrative medicine. My Clinical Experience: LDN + Ketosis In my own practice, I've had the opportunity to work with numerous Sjögren's patients—both those with classic presentations (predominant dry eyes and dry mouth) and those with non-classic, systemic manifestations (fatigue, widespread pain, neuropathy, brain fog). What I've observed has been genuinely exciting. Patients who combine LDN with nutritional ketosis have shown excellent responses. The rationale for this combination makes physiological sense: ketosis itself has well-documented anti-inflammatory and neuroprotective effects, and ketones serve as an alternative fuel source that may support mitochondrial function in the setting of chronic inflammation. When paired with LDN's immunomodulatory properties, the synergy appears meaningful. I've seen patients experience significant reductions in fatigue and pain, clearing of brain fog, and improvements in overall quality of life. Some patients with classic sicca symptoms have even reported modest improvements in dryness, though as the literature suggests, systemic symptoms tend to respond more robustly than glandular dysfunction. This combination—LDN plus therapeutic ketosis—represents the kind of integrative approach I find most valuable: addressing the underlying inflammatory and metabolic terrain rather than simply suppressing symptoms. It's low-risk, well-tolerated, and puts patients in an active role in their own healing. Of course, my clinical observations aren't controlled trials, and individual responses vary. But when conventional options have been exhausted or are poorly tolerated, this approach offers real hope. The Bottom Line Sjögren's syndrome remains challenging to treat, particularly for patients whose primary complaints are fatigue, pain, and cognitive difficulties rather than (or in addition to) dryness. Low-dose naltrexone offers a mechanistically plausible, low-risk option that has shown consistent benefits in published case reports and in clinical practice. For patients interested in optimizing their response, combining LDN with nutritional ketosis represents a promising integrative strategy. While we await larger controlled trials, the favorable safety profile and clinical observations to date make this an approach worth considering—ideally in partnership with healthcare providers who understand both the potential and the limitations of this therapy. Low-Dose Naltrexone LDN in the Management of Sjögren's Syndrome At www.directinegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Carsons, S. E., & Blum, M. A. (2025). Sjogren syndrome. In StatPearls . StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK431049/ Cleveland Clinic. (n.d.). Sjogren's syndrome . https://my.clevelandclinic.org/health/diseases/4929-sjogrens-syndrome de Carvalho, J. F., & Skare, T. (2023). Low-dose naltrexone in rheumatological diseases. Mediterranean Journal of Rheumatology, 34 (1), 1–6. https://doi.org/10.31138/mjr.34.1.1 LDN Research Trust. (n.d.-a). How low dose naltrexone works . https://ldnresearchtrust.org/how-low-dose-naltrexone-works LDN Research Trust. (n.d.-b). Low dose naltrexone (LDN) and Sjogren's syndrome . https://ldnresearchtrust.org/low-dose-naltrexone-ldn-and-sjogren%E2%80%99s-syndrome-dr-pamela-smith Mayo Clinic. (n.d.). Sjogren's syndrome: Symptoms and causes . https://www.mayoclinic.org/diseases-conditions/sjogrens-syndrome/symptoms-causes/syc-20353216 National Health Service. (n.d.). Sjögren's syndrome . https://www.nhs.uk/conditions/sjogrens-syndrome/ Sjogren's Foundation. (n.d.). Understanding Sjogren's . https://sjogrens.org/understanding-sjogrens The American College of Rheumatology. (n.d.). Sjogren's disease . https://rheumatology.org/patients/sjogrens-disease Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences, 6 (4), 82. https://doi.org/10.3390/medsci6040082 Zashin, S. (2019). Sjogren's syndrome: Clinical benefits of low-dose naltrexone therapy. Cureus, 11 (3), e4225. https://doi.org/10.7759/cureus.4225 Zashin, S. (2020). Sjogren's syndrome and clinical benefits of low-dose naltrexone therapy: Additional case reports. Cureus, 12 (7), e8948. https://doi.org/10.7759/cureus.8948

Yoon Hang "John" Kim, MD, MPH About the Author Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN (Low-Dose Naltrexone) for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles on LDN and integrative medicine, and has helped establish integrative medicine programs at institutions nationwide. Professional: www.yoonhangkim.com   |  Clinical: www.directintegrativecare.com A Personal Note Before diving into the clinical details, I want to share something personal. A close family member of mine was completely incapacitated by mold-related illness. The fatigue was crushing, the brain fog impenetrable, and the road to diagnosis frustratingly long. Watching someone you love struggle with a condition that many physicians don’t recognize—or worse, dismiss—is heartbreaking. But here’s the good news: they made a full recovery. It wasn’t quick, it wasn’t easy, and it required a systematic approach that addressed every layer of the illness. That experience deepened my commitment to understanding mold-related conditions and helping others navigate this challenging journey. If you or someone you love is struggling, please know that recovery is possible. Healing from Mold Illness: A Comprehensive Approach Integrating Low-Dose Naltrexone Introduction Mold-related illness—often called Chronic Inflammatory Response Syndrome (CIRS)—is one of the most misunderstood conditions in modern medicine. It arises from exposure to biotoxins in water-damaged buildings and triggers a cascade of immune dysregulation that can affect virtually every system in the body. Patients often present with an overwhelming constellation of symptoms: crushing fatigue, cognitive impairment (the dreaded "brain fog"), chronic pain, and a profound sense that something is deeply wrong—even when standard labs come back "normal." What many people don’t realize is that up to 25% of the population carries genetic susceptibility to CIRS (Dooley et al., 2024). That’s a staggering number. A recent systematic review confirmed that the Shoemaker Protocol remains the only treatment with documented clinical efficacy for CIRS—and it works better than protocols designed for similar conditions like ME/CFS (Dooley et al., 2024). In my practice, I’ve found that while foundational interventions—removing exposure, binding toxins, treating colonization—form the backbone of treatment, adjunctive therapies like low-dose naltrexone (LDN) can make a meaningful difference. LDN doesn’t cure mold illness, but for many patients, it helps calm the immune storm enough to make the deeper healing work more tolerable and effective. This article walks through a comprehensive approach to mold-related illness, combining validated protocols with promising supportive therapies. Step 1: Find the Mold and Get Away from It I cannot overstate this: you cannot heal in a toxic environment . It’s like trying to put out a fire while someone keeps pouring gasoline on it. Dr. Bruce Hoffman puts it bluntly: "For many people, this is the most critical, yet most difficult step. Without removing exposure, treatment cannot succeed" (Hoffman, n.d.). I know this step can feel impossible. Sometimes it means leaving your home, your job, or making financial sacrifices that seem unreasonable. But I’ve seen patients spin their wheels for years—taking every supplement, trying every protocol—only to finally improve when they addressed the exposure. The body simply cannot outpace ongoing toxic exposure. Testing Your Environment The ERMI (Environmental Relative Moldiness Index) test provides a quantitative PCR analysis of 36 mold species. Dr. Shoemaker’s research suggests a safe score is ≤2 for most patients, and below -1 for those with highly elevated C4a levels (Shoemaker, 2010). After remediation, the HERTSMI-2 test can verify whether the building is safe to re-enter—scores below 11 are generally the target. Getting It Done Right Professional remediation should follow EPA and IICRC guidelines. This isn’t a DIY project—improper remediation can actually make things worse by stirring up spores. Key priorities include fixing water intrusion, removing damaged materials, controlling humidity, and using HEPA filtration. And here’s something patients often underestimate: re-exposure can happen within 15 minutes of entering a contaminated building. Stay out until it’s truly safe. Step 2: Bind and Eliminate the Toxins Here’s the frustrating biology: in genetically susceptible people, about 95% of bile—which carries biotoxins—gets reabsorbed in the gut and recirculated. It’s like a merry-go-round of toxins that never stops. Binders interrupt this cycle by grabbing onto the toxins in your gut and escorting them out through your stool. The Gold Standard: Cholestyramine Cholestyramine (CSM) remains the most effective binder we have, backed by two double-blind, placebo-controlled studies. It works because its positive charge attracts negatively charged biotoxins. The standard protocol calls for four doses daily on an empty stomach—which, I’ll admit, can be challenging to maintain. Many patients start with Welchol, which is easier to tolerate even if it’s only about 25% as effective (Shoemaker, 2010). Other Options For patients who can’t tolerate prescription binders, we sometimes turn to activated charcoal, bentonite clay, chlorella, or zeolite. These don’t have the same evidence base, but Dr. Neil Nathan has observed that different mycotoxins may bind preferentially to different agents—for instance, bentonite and charcoal seem to work well for trichothecenes (Nathan, n.d.). Some clinicians have also found success with okra and beet extracts, though peer-reviewed data is still pending. Step 3: Clear the Colonizers Most CIRS patients harbor something called MARCoNS—Multiple Antibiotic Resistant Coagulase Negative Staphylococci—deep in their nasal passages. These bacteria form protective biofilms and release toxins that break down MSH (melanocyte-stimulating hormone), a key anti-inflammatory peptide. It’s a vicious cycle: low MSH allows MARCoNS to thrive, and MARCoNS further suppress MSH (Shoemaker, 2010). Testing A deep nasal swab sent to a specialized lab like MicrobiologyDX can identify MARCoNS. About 80% of CIRS patients test positive, with roughly 60% showing methicillin resistance. The culture also reveals which antibiotics the bacteria are resistant to—critical information for treatment planning. Treatment BEG nasal spray—a compounded formula containing Bactroban, EDTA, and Gentamicin—is the primary treatment. The EDTA dissolves the biofilm, allowing the antibiotics to reach the bacteria. The standard protocol is two sprays in each nostril, three times daily, for at least a month. Some stubborn cases require up to six months of treatment. A word of caution: when MARCoNS die, they release endotoxins that can temporarily worsen symptoms. I recommend patients be on an effective binder for at least a month before starting nasal treatment. Alternatives for those who can’t tolerate BEG include colloidal silver rinses, EDTA-only formulations, or Xlear (xylitol-based spray). Some practitioners are even exploring probiotic nasal sprays to reestablish healthy flora. Don’t Forget the Fungus Fungal colonization of the sinuses is often overlooked but can produce mycotoxins locally. Treatment may include amphotericin B nasal spray, oral antifungals like itraconazole, and biofilm disruptors. Interestingly, addressing sinus mold often resolves MARCoNS simultaneously—the bacterial and fungal biofilms seem to support each other. Step 4: Support Your Body’s Detox Pathways Binders are essential, but they’re only part of the equation. The body has its own detoxification machinery—liver, kidneys, lymphatics, skin—and that machinery needs support, especially when it’s been overwhelmed by chronic toxin exposure. Glutathione: The Master Antioxidant Glutathione depletion is nearly universal in patients with mycotoxin exposure (Guilford & Hope, 2014). This matters because glutathione is central to phase II liver detoxification and protects cells from oxidative damage. Supplementation options include liposomal glutathione (oral), N-acetylcysteine/NAC (a precursor), IV glutathione for more severe cases, and intranasal glutathione for sinus and neurological support. A survey found that over 62% of patients using intranasal glutathione reported meaningful benefits (Hope, 2013). Additional Support Methylation support (methylfolate, methylcobalamin, SAMe) helps keep detox pathways running smoothly. Infrared sauna therapy promotes toxin elimination through sweat—preliminary research shows reduced mycotoxin levels when combined with other therapies (Rea et al., 2009). Phosphatidylcholine supports cell membranes and liver function. And don’t underestimate the basics: vitamin D, magnesium, zinc, CoQ10, and B vitamins are commonly depleted in CIRS patients and should be repleted. Step 5: Calm the Allergic Fire Many mold patients develop what we call Mast Cell Activation Syndrome (MCAS)—their mast cells become hypersensitive and release histamine and other inflammatory chemicals at the slightest provocation. This can make treatment incredibly difficult because patients react to everything: foods, supplements, even medications meant to help them. Strategies That Help H1 and H2 antihistamines can block histamine effects. Mast cell stabilizers like ketotifen and cromolyn sodium prevent degranulation. Natural options include quercetin and other bioflavonoids. A low-histamine diet reduces triggers. DAO (diamine oxidase) supplementation helps those with impaired histamine breakdown. Perhaps most importantly, patients need to identify and avoid their personal triggers—which can include certain foods, fragrances, temperature extremes, and stress. The Cell Danger Response Some researchers believe that mold toxicity triggers a "Cell Danger Response"—a protective shift where cells prioritize defense over energy production. This may explain why so many CIRS patients feel stuck in a "freeze" state, unable to muster the energy for normal activities. Supporting mitochondrial function with nutrients like CoQ10, ribose, and carnitine may help cells transition out of this defensive mode. Where Low-Dose Naltrexone Fits In Now we get to LDN—and I want to be clear about what it is and isn’t. LDN is not  a cure for mold illness. It doesn’t kill mold, it doesn’t bind mycotoxins, and it won’t work if you skip the foundational steps. But for many patients, it’s a valuable tool that helps calm the immune chaos and makes everything else work better. How It Works At standard doses (50 mg), naltrexone blocks opioid receptors and is used for addiction treatment. At low doses (typically 1.5–4.5 mg), it does something quite different: it briefly blocks opioid receptors, triggering a rebound increase in endorphins and enkephalins—the body’s natural feel-good and immune-regulating chemicals. LDN also inhibits Toll-like receptor 4 (TLR4) on microglial cells in the brain, reducing the neuroinflammation that causes so much of the cognitive dysfunction in mold illness. It shifts cytokine balance away from pro-inflammatory (IL-6, TNF-α, TGF-β1) and toward regulatory (IL-10). For patients with MCAS, this shift can be game-changing—the LDN Research Trust reports that about 60% of MCAS patients experienced improvement in symptoms like brain fog, fatigue, and GI distress after starting LDN. When to Introduce It Timing matters. I typically introduce LDN after  patients have addressed environmental exposure, started binder therapy, and achieved at least partial reduction in their inflammatory burden. Starting too early—when the immune system is still in full-blown crisis mode—can sometimes backfire and intensify symptoms. Clinical observation suggests that patients with the HLA type 4-3-53 may respond particularly well to LDN. Patient surveys indicate that most who tried LDN for CIRS rated it "critically important or very helpful" in their recovery (Richmond Functional Medicine, 2024). And unlike NSAIDs—which carry risks of GI bleeding, kidney damage, and cardiovascular problems—LDN’s side effects are minimal and usually temporary. Dosing: Low and Slow For mold patients, especially those with chemical sensitivity, I start very low—0.25 to 0.5 mg—and titrate up gradually over weeks. The goal is usually 1.5–4.5 mg, taken at bedtime to align with natural endorphin production. Some patients experience vivid dreams or insomnia initially; if this persists, switching to morning dosing often helps. Important caveats: LDN is contraindicated if you’re taking opioid medications (it can trigger withdrawal), and caution is warranted in liver impairment. You’ll need a compounding pharmacy—standard naltrexone comes in 50 mg tablets, far too high for LDN use. Other Functional Medicine Approaches Worth Considering Heal the Gut Mycotoxins wreak havoc on the gut microbiome, reducing beneficial species like Lactobacillus reuteri and decreasing overall diversity. Research shows that a healthy gut microbiota can actually help eliminate mycotoxins naturally (Draper et al., 2021). Specific probiotics (Lactobacillus rhamnosus, Bifidobacterium bifidum), prebiotics, and an anti-inflammatory diet that avoids commonly contaminated foods (coffee, nuts, dried fruit, rice) all support gut recovery. Follow the Biomarkers The Shoemaker Protocol includes sequential correction of specific inflammatory markers: ADH/osmolality (desmopressin), MMP-9 (omega-3s and no-amylose diet), VEGF, C3a (statins), C4a, TGF-β1 (losartan or VIP), and MSH. The final step—VIP nasal spray—can only begin after MARCoNS is cleared. It’s methodical, but there’s a reason: each step builds on the last. Emerging Options Mild hyperbaric oxygen therapy (mHBOT) has shown promise in case reports, with one recent case documenting complete symptom resolution after 40 sessions (Frontiers in Immunology, 2025). Ozone therapy, peptide protocols, and other integrative approaches continue to be explored. These aren’t first-line treatments, but for refractory cases, they may offer additional tools. Healing from Mold Illness: A Comprehensive Approach Integrating Low-Dose Naltrexone Final Thoughts Recovering from mold illness is a marathon, not a sprint. It requires patience, persistence, and a systematic approach that addresses every layer of the problem: the environment, the toxins, the colonizers, the depleted detox pathways, and the overactive immune system. LDN isn’t a magic bullet, but for many patients, it’s a valuable piece of the puzzle. Its ability to calm neuroinflammation, stabilize mast cells, and reduce the persistent fatigue of CIRS makes it a rational addition to the toolkit—as long as it’s integrated with, not substituted for, the foundational treatments. I think of it this way: the Shoemaker Protocol is the road map, and LDN is one of the vehicles that can make the journey more bearable. We still need better research—randomized controlled trials specifically in CIRS populations—but the clinical experience and mechanistic rationale are compelling enough that I regularly incorporate LDN into my treatment plans. If you’re struggling with mold illness, know that recovery is possible. I’ve seen it in my patients, and I’ve seen it in my own family. It takes time, it takes the right approach, and it takes a willingness to address the root causes—but the other side of this illness is absolutely reachable. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN (Low-Dose Naltrexone) for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles on LDN and integrative medicine, and has helped establish integrative medicine programs at institutions nationwide. Direct Integrative Care At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality. Yoon Hang Kim, MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Dooley, M., Vukelic, A., & Jim, L. (2024). Chronic inflammatory response syndrome: A review of the evidence of clinical efficacy of treatment. Annals of Medicine and Surgery, 86 (12), 7248–7254. https://doi.org/10.1097/MS9.0000000000002718 Guilford, F. T., & Hope, J. (2014). Deficient glutathione in the pathophysiology of mycotoxin-related illness. Toxins, 6 (2), 608–623. https://doi.org/10.3390/toxins6020608 Hoffman, B. (n.d.). 12 Steps of the Shoemaker Protocol. Hoffman Centre for Integrative Medicine. https://www.drbrucehoffman.com/post/shoemaker-protocol Holtorf, K. (2022). Mold illness and CIRS. In L. Elsegood (Ed.), The LDN Book 3: Low dose naltrexone—The latest research on viral infections, long COVID, mold toxicity, longevity, cancer, depression and more . LDN Research Trust. Hope, J. (2013). A review of the mechanism of injury and treatment approaches for illness resulting from exposure to water-damaged buildings, mold, and mycotoxins. The Scientific World Journal, 2013 , 767482. https://doi.org/10.1155/2013/767482 LDN Research Trust. (n.d.). Mold toxicity: Can low dose naltrexone help? https://ldnresearchtrust.org/mold-toxicity-can-low-dose-naltrexone-ldn-help Patten, D. K., Schultz, B. G., & Berlau, D. J. (2018). The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy, 38 (3), 382–389. https://doi.org/10.1002/phar.2086 Rea, W. J., Pan, Y., & Griffiths, B. (2009). The treatment of patients with mycotoxin-induced disease. Toxicology and Industrial Health, 25 (9–10), 711–714. https://doi.org/10.1177/0748233709348281 Shoemaker, R. C. (2010). Surviving mold: Life in the era of dangerous buildings . Otter Bay Books. Shoemaker, R. C., House, D., & Ryan, J. C. (2013). Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings. Health, 5 (3), 396–401. https://doi.org/10.4236/health.2013.53053 Surviving Mold. (n.d.). The 12-step Shoemaker Protocol overview. https://www.survivingmold.com/legal-resources/12-step-protocol-overview Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451–459. https://doi.org/10.1007/s10067-014-2517-2 Disclaimer: This article is for educational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare provider familiar with biotoxin illness. Individual responses to treatment vary, and protocols should be tailored to each patient’s specific presentation and tolerances.

Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com In integrative medicine and functional medicine, women experiencing perimenopause and menopause often seek natural menopause supplements to address hormonal imbalances that conventional approaches may not fully resolve. Among the botanical and nutritional options available, Diindolylmethane (DIM) and Vitex agnus-castus (chasteberry) stand out as particularly useful tools—DIM for supporting healthy estrogen metabolism, and chasteberry for optimizing pituitary signaling. This review explores their biochemical mechanisms, clinical evidence, safety profiles, and practical applications. Because accurate diagnosis matters, I'll also discuss how these supplements fit within personalized treatment plans. If you're new to integrative medicine, expect your first appointment to involve thorough assessment and collaborative goal-setting—these supplements work best as part of a broader therapeutic relationship, not as standalone fixes. The Clinical Challenge of Menopausal Hormone Dysregulation Before diving into specific supplements, it helps to understand why so many women seek alternatives to conventional hormone replacement therapy. The menopausal transition involves far more than simple estrogen decline—it represents a fundamental reorganization of the hypothalamic-pituitary-ovarian axis that unfolds over years, often with unpredictable symptom patterns. During perimenopause, the clinical picture is frequently one of relative estrogen dominance rather than deficiency. Irregular ovulation leads to inadequate progesterone production, while estrogen levels may actually surge erratically before their eventual decline. This creates symptoms like breast tenderness, bloating, mood instability, heavy bleeding, and sleep disruption—symptoms that don't always respond well to estrogen-based therapies. Integrative and functional medicine approaches recognize that optimizing how the body processes and eliminates estrogen may be as important as addressing absolute hormone levels. This is where DIM and chasteberry offer their greatest clinical utility. Understanding DIM in Integrative Medicine for Menopause DIM is derived from cruciferous vegetables—broccoli, cauliflower, Brussels sprouts, cabbage. When we eat these vegetables, a precursor compound called indole-3-carbinol (I3C) converts in the stomach to form DIM, the bioactive metabolite responsible for most clinical effects. Beyond menopause, DIM is being explored for other conditions related to estrogen metabolism. The Biochemistry of Estrogen Metabolism To appreciate how DIM works, we need to understand estrogen metabolism. Estrogens—primarily estradiol (E2), estrone (E1), and estriol (E3)—undergo Phase 1 liver metabolism via cytochrome P450 enzymes, producing hydroxylated metabolites through three primary pathways: 2-hydroxyestrone (2-OHE1)  is generally considered the most favorable metabolite, with weak estrogenic activity and potential antiestrogenic effects in breast tissue. 4-hydroxyestrone (4-OHE1)  is more concerning—it's associated with oxidative DNA damage and potentially genotoxic quinone formation. 16α-hydroxyestrone (16α-OHE1)  has strong estrogenic activity and may promote cellular proliferation in estrogen-sensitive tissues. The ratio of 2-OHE1 to 16α-OHE1 has attracted significant research attention as a potential biomarker for estrogen-related disease risk, though clinical correlations remain an active area of investigation. Mechanisms of DIM as a Functional Medicine Tool DIM modulates Phase 1 liver detoxification by influencing the cytochrome P450 enzyme CYP1A1. Its preferential induction of this enzyme favors the 2-hydroxyestrone pathway over the 16α-hydroxyestrone route. This metabolic shift can reduce estrogenic signaling in peripheral tissues, making DIM valuable for addressing estrogen dominance symptoms. It's worth noting that DIM supports hormonal balance for chronic symptom management—it's not intended for acute conditions or as a quick fix. Beyond Phase 1 metabolism, DIM may support Phase 2 conjugation pathways and promote healthier estrogen receptor signaling. Some research suggests DIM acts as a selective estrogen receptor modulator (SERM), potentially blocking more potent estrogens from receptor binding while exerting mild estrogenic effects of its own. This nuanced mechanism may explain its clinical utility across varying hormonal states. DIM also demonstrates anti-inflammatory properties through NF-κB signaling modulation and may support cellular health through effects on cell cycle regulation and apoptotic pathways—effects that extend its potential applications beyond simple hormone balancing. Clinical Evidence for DIM in Menopause Management Research supports DIM's capacity to alter estrogen metabolism meaningfully. Studies in postmenopausal women, including those on hormone therapy, show significant improvements in urinary estrogen profiles. Supplementation typically produces measurable increases in the 2-OHE1/16α-OHE1 ratio within weeks, suggesting relatively rapid metabolic effects. One study also demonstrated DIM's anti-inflammatory properties and positive impact on PMS symptoms, further supporting its therapeutic potential. A particularly relevant consideration: DIM's interaction with exogenous hormone therapy. By enhancing estrogen clearance, DIM may reduce the biological activity of administered hormones. This can be therapeutically useful when estrogen-dominant symptoms persist despite standard HRT protocols, but patients on hormone therapy may need dose adjustments when adding DIM. While large-scale trials specifically examining DIM for menopausal symptom relief remain limited, clinical experience and mechanistic data support its use for symptoms associated with estrogen excess or impaired estrogen metabolism. Breast tenderness, cyclical bloating, fibrocystic breast changes, and heavy perimenopausal bleeding often respond favorably, particularly when these symptoms suggest relative estrogen dominance. Practical Considerations for DIM Supplementation Bioavailability matters with DIM supplements. The compound is lipophilic and poorly absorbed in its native form. Enhanced-bioavailability formulations using microencapsulation or phospholipid complexes may offer superior absorption, though comparative clinical data remains limited. Standard dosing typically ranges from 100-300 mg daily of enhanced-bioavailability DIM. Optimal doses vary based on body weight, symptom severity, and concurrent hormone use. Starting low and titrating based on response is reasonable. Common side effects are generally mild: temporary darkening of urine (with a characteristic odor reflecting metabolite excretion), mild GI upset, or headache during initial use. These typically resolve with continued use or dose adjustment. DIM is generally considered safe for short-term use, but long-term safety hasn't been well established. Chasteberry's Role in Functional Medicine for Hormonal Symptoms Chasteberry (Vitex agnus-castus) is one of the most extensively studied botanical medicines for female hormonal complaints. Native to the Mediterranean, it's been used medicinally for over two thousand years—historical applications ranged from promoting lactation to suppressing libido (hence "chasteberry"). During the Middle Ages, monks used it to lower sexual desire. Today it's commonly used as an herbal supplement in integrative medicine, and modern research has refined our understanding of its mechanisms. How Chasteberry Works in Integrative Approaches Chasteberry's primary mechanism involves dopaminergic activity through binding to dopamine D2 receptors in the anterior pituitary. This suppresses prolactin secretion from lactotroph cells—an effect with significant downstream hormonal consequences. Prolactin, while essential for lactation, inhibits the hypothalamic-pituitary-gonadal axis when chronically elevated. Even modest prolactin elevations within the "normal" lab range can impair progesterone production and contribute to luteal phase deficiency. By normalizing prolactin levels, chasteberry indirectly supports LH pulsatility and enhances corpus luteum function, improving progesterone output. This makes chasteberry particularly valuable for premenstrual and perimenopausal presentations characterized by relative progesterone deficiency. Unlike bioidentical progesterone supplementation, which directly replaces the hormone, chasteberry works upstream to support the body's own progesterone production—a distinction that appeals to patients seeking more physiologic interventions. Beyond dopaminergic effects, chasteberry extracts contain compounds that interact with opioid receptors (particularly mu and kappa subtypes) and may bind to estrogen receptor beta. These additional mechanisms likely contribute to effects on mood, pain perception, and vasomotor symptoms, though the clinical significance of each pathway remains under investigation. Evidence-Based Benefits of Chasteberry for Menopause The clinical evidence for chasteberry in menopause continues to grow. Randomized controlled trials demonstrate significant reductions in vasomotor symptoms compared to placebo, with effect sizes approaching low-dose hormone therapy in some studies. Chasteberry has also been shown to help alleviate other menopausal symptoms, making it a promising option. Research using the Greene Climacteric Scale—a validated instrument measuring menopausal symptoms across vasomotor, psychological, and somatic domains—shows significant improvements in total scores and subscales with chasteberry supplementation. Anxiety reduction appears particularly robust, consistent with its dopaminergic and opioidergic activities. Meta-analyses examining chasteberry for PMS confirm strong efficacy, with improvements across physical and psychological symptom domains. Given the overlapping symptoms between severe PMS and perimenopause, these findings support chasteberry's utility during the menopausal transition. Emerging research also suggests potential benefits for sleep quality, mood stability, and cognitive symptoms during menopause, though these applications need further controlled investigation. Dosing and Formulation Considerations Chasteberry supplements vary considerably in preparation methods, standardization, and dosages. Traditional preparations used dried berries, while modern standardized extracts concentrate specific marker compounds. Standard doses include 20-40 mg daily of concentrated extract (often standardized to agnuside or casticin content). The German Commission E recommends 30-40 mg daily of dried fruit extract. Clinical response typically requires sustained use over several menstrual cycles, with most studies showing significant effects after three months. This delayed onset reflects the time needed for hormonal recalibration—something to communicate to patients so they have realistic expectations. Combining DIM and Chasteberry: Synergy in Functional Medicine In practice, combining DIM and chasteberry targets complementary pathways—peripheral estrogen detoxification and central hormonal signaling—for enhanced relief in estrogen-dominant conditions. Theoretical and Practical Synergies The mechanistic rationale is compelling. DIM addresses estrogen metabolism at the hepatic level, promoting conversion to less proliferative metabolites and enhancing clearance. Simultaneously, chasteberry optimizes pituitary signaling, supports progesterone production, and reduces inhibitory effects of elevated prolactin. For the perimenopausal woman with erratic estrogen levels and inadequate progesterone opposition, this combination addresses both sides of the hormonal equation. The typical presentation suitable for this combination includes heavy or irregular periods, breast tenderness, bloating, mood instability, and sleep disruption—symptoms suggesting both estrogen excess and progesterone deficiency. While no RCTs have evaluated DIM and chasteberry together, mechanistic rationale combined with clinical experience supports this pairing. Practitioners report benefits for mood stabilization, reduced hot flash frequency and severity, more regular cycles during perimenopause, and improvement in estrogen-dominant symptoms. The combination may be particularly valuable when single-agent therapy provides incomplete relief, or when assessment reveals dysfunction in both estrogen metabolism and progesterone production. Clinical Implementation Strategies Several practical considerations guide clinical decision-making: Sequential vs. Simultaneous Initiation : Some practitioners prefer introducing one agent at a time to assess individual response; others initiate both simultaneously when the clinical picture strongly supports combination therapy. Either approach works depending on circumstances. Monitoring Parameters : Symptom diaries, menstrual patterns, and periodic hormone testing (including estrogen metabolite ratios when available) help optimize dosing. The 2-OHE1/16α-OHE1 ratio provides objective data on DIM's metabolic effects. Duration of Therapy : Both agents typically require sustained use. Three-month trial periods with systematic reassessment allow adequate time for hormonal recalibration. Transition Strategies : As patients progress through menopause, their hormonal needs evolve. The combination that addresses perimenopausal estrogen dominance may need modification when absolute estrogen deficiency predominates later. Patients should talk with their healthcare provider before starting or combining these supplements to ensure safety and appropriate monitoring. Safety Considerations in Integrative and Functional Medicine Both DIM and chasteberry have favorable safety profiles at standard doses, though several considerations warrant attention. DIM Safety Profile DIM is generally well-tolerated at 100-300 mg daily of enhanced-bioavailability preparations. Common effects include darkened urine, mild GI symptoms, and occasional headache—typically transient and dose-related. More significant considerations: Drug Interactions : DIM's induction of cytochrome P450 enzymes could theoretically affect metabolism of medications cleared through these pathways. Clinically significant interactions appear uncommon, but awareness is warranted for medications with narrow therapeutic windows. Hormone Therapy Interactions : DIM may enhance estrogen clearance, potentially reducing HRT efficacy. Monitor for symptom recurrence that might indicate need for hormone dose adjustment. Hormone-Sensitive Conditions : Patients with hormone-sensitive cancers should use DIM only under oncologic supervision. Theoretical benefits of favorable estrogen metabolism must be weighed against the complexity of these conditions. Chasteberry Safety Profile Chasteberry demonstrates excellent tolerability in clinical trials, with adverse event rates similar to placebo. Side effects are typically mild: GI upset, headache, skin reactions. Important considerations: Dopaminergic Medications : Given chasteberry's D2 receptor activity, theoretical interactions exist with dopaminergic medications including certain antipsychotics, antiemetics, and Parkinson's disease treatments. Clinical significance is uncertain, but concurrent use warrants monitoring. Hormone-Sensitive Conditions : Patients with hormone-sensitive cancers should use chasteberry only under appropriate supervision. Pregnancy : Discontinue if pregnancy occurs—effects on early pregnancy aren't fully characterized. Fertility Treatments : Women undergoing assisted reproductive technologies should generally avoid chasteberry, as its pituitary effects could interfere with treatment protocols. Laboratory Assessment in Functional Medicine Practice Specialized testing can guide and monitor botanical hormone support. Urinary Estrogen Metabolites Comprehensive urinary hormone panels measuring estrogen metabolites provide objective data on metabolism pathways. The 2-OHE1/16α-OHE1 ratio serves as a primary marker. These tests also assess 4-hydroxyestrone levels and methylation status of catechol estrogens, providing a complete picture. Serial testing before and after DIM initiation can document metabolic improvements and guide dose optimization. Serum Hormone Panels Standard assessments including estradiol, progesterone, FSH, LH, and prolactin help characterize the hormonal landscape. Prolactin measurement is particularly relevant when considering chasteberry—elevated baseline levels predict stronger response. Timing relative to menstrual cycle significantly affects interpretation and should be standardized. DUTCH Testing The Dried Urine Test for Comprehensive Hormones (DUTCH) combines assessment of sex hormones, their metabolites, adrenal hormones, and organic acids in a single panel—useful for protocol design and monitoring. Menopause and Chronic Disease Prevention Menopause isn't just about managing hot flashes—it's a pivotal moment for long-term health. The North American Menopause Society and American College of Obstetricians and Gynecologists recognize that this transition significantly elevates risks for cardiovascular disease, osteoporosis, and metabolic dysfunction including type 2 diabetes. Functional medicine practitioners view menopause as an opportunity for proactive health optimization, not just symptom suppression. Through comprehensive testing and individualized risk assessment, we can guide women toward interventions that demonstrably improve long-term outcomes. Botanical therapeutics like chasteberry have shown clinical efficacy for reducing menopausal symptoms and supporting hormonal balance. When integrated thoughtfully, they can help alleviate breast tenderness, mood swings, and vasomotor symptoms while improving quality of life. Complementary approaches also deserve mention. Research from institutions like the University of Arizona's Andrew Weil Center for Integrative Medicine supports practices like tai chi and acupuncture for reducing hot flash frequency and severity. These address physical symptoms while also supporting psychological well-being and stress resilience. The National Center for Complementary and Integrative Health (NCCIH), part of the NIH, provides helpful resources for both practitioners and patients seeking safe, effective integrative strategies. Using these resources, women can make informed decisions about supplements, lifestyle modifications, and complementary therapies that fit their individual situations. The functional medicine model emphasizes prevention and patient empowerment throughout menopause. Through personalized nutrition, targeted supplementation, and evidence-based complementary approaches, women can meaningfully reduce chronic disease risk while effectively managing symptoms. A Note on Provider Training Delivering quality integrative menopause care requires specialized training. The functional medicine model—championed by pioneers like Dr. Andrew Weil—takes a whole-person approach addressing physical, mental, and emotional aspects of menopausal health. Institutions like the Cleveland Clinic Center for Functional Medicine and University of Arizona offer programs covering dietary supplements, complementary therapies like medical acupuncture, and lifestyle interventions. This training helps practitioners deliver personalized care that considers each woman's unique factors—from nutrition and stress to chronic conditions and risk assessment. Well-trained providers can guide women through menopause's complexities, offering evidence-based recommendations while helping them understand the risks and benefits of various interventions. Ultimately, prioritizing provider education ensures women receive integrative, whole-person care that addresses their individual needs and promotes optimal health throughout midlife and beyond. Integration with Comprehensive Menopause Management DIM and chasteberry work best as components of comprehensive integrative approaches. Foundational interventions remain essential. Dietary Foundations Cruciferous vegetables provide dietary DIM and I3C along with fiber, vitamins, minerals, and other beneficial phytochemicals. While supplemental DIM delivers more concentrated effects, dietary intake supports overall metabolic health regardless of supplementation status. Mediterranean dietary patterns—emphasizing plant foods, healthy fats, and moderate protein—provide an evidence-based foundation for hormonal health and cardiovascular protection during menopause. Lifestyle Factors Sleep optimization, stress management, and appropriate physical activity profoundly influence hormonal balance and symptom severity. These modifiable factors often receive insufficient attention yet may determine whether botanical interventions succeed. Regular physical activity—particularly resistance training and weight-bearing exercise—supports bone health, metabolic function, and mood stability. Both excessive exercise and sedentary behavior can worsen hormonal imbalances. Additional Botanical and Nutritional Support DIM and chasteberry often function within broader protocols that may include: Omega-3 fatty acids  for anti-inflammatory effects and cardiovascular protection Magnesium  for sleep, mood, and neuromuscular function B vitamins  supporting estrogen methylation and neurotransmitter synthesis Adaptogenic herbs  like ashwagandha or rhodiola for stress resilience Black cohosh  for vasomotor symptom relief through different mechanisms Selection and combination should be individualized based on comprehensive assessment. Conclusion: Optimizing Menopause Care with Supplements in Integrative Medicine DIM and chasteberry represent promising menopause supplements in integrative and functional medicine, providing evidence-based options that address underlying physiologic mechanisms rather than simply masking symptoms. Their complementary actions on estrogen metabolism and pituitary regulation make them particularly valuable as combination therapy for estrogen-dominant presentations common during perimenopause. However, these botanical medicines should complement—not replace—established therapies when indicated. For women with severe vasomotor symptoms, genitourinary syndrome of menopause, or significant osteoporosis risk, hormone replacement therapy may remain the most effective intervention. DIM and chasteberry can still serve as valuable adjuncts, supporting hormone metabolism and addressing symptoms that persist despite HRT. Future research on combined efficacy, optimal dosing, and long-term safety will further clarify their role in evidence-based integrative menopause care. For now, their favorable safety profiles, mechanistic rationale, and clinical experience support thoughtful integration into comprehensive menopausal health protocols under appropriate clinical guidance. References Arslan, A. A., & Zeleniuch-Jacquotte, A. (2011). 3,3′-Diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: A pilot study. Thyroid, 21 (3), 299–304. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048776/ Dawood, M. Y., & Khan-Dawood, F. S. (2025). The impact of 3,3'-diindolylmethane on estradiol and estrogen metabolites among postmenopausal women on hormone therapy. Menopause, 32 (1), 45–52. https://pubmed.ncbi.nlm.nih.gov/ Intimate Rose. (n.d.). What is DIM and how does it compare to Vitex?   https://www.intimaterose.com/ Integrative Menopause MD. (2025). Perimenopause? Tame the hormonal chaos naturally with Vitex . https://www.integrativemenopausemd.com/ Memorial Sloan Kettering Cancer Center. (2021). Chasteberry . https://www.mskcc.org/cancer-care/integrative-medicine/herbs/chasteberry Memorial Sloan Kettering Cancer Center. (n.d.). Diindolylmethane . https://www.mskcc.org/cancer-care/integrative-medicine/herbs/diindolylmethane Rafieian-Kopaei, M., & Movahedi, M. (2017). Systematic review of premenstrual, postmenstrual and infertility disorders of Vitex agnus-castus. Electronic Physician, 9 (1), 3685–3689. https://pubmed.ncbi.nlm.nih.gov/ Roozbeh, N., Ghazanfarpour, M., Khadivzadeh, T., Kargarfard, L., Dizavandi, F. R., & Shariati, K. (2021). Effect of Vitex agnus-castus on depression, anxiety, and sleep disorders in patients with premenstrual dysphoric disorder: A systematic review and meta-analysis. Journal of Obstetrics and Gynaecology Research, 47 (11), 3794–3803. https://www.brieflands.com/ van Die, M. D., Burger, H. G., Teede, H. J., & Bone, K. M. (2012). Vitex agnus-castus extracts for female reproductive disorders: A systematic review of clinical trials. Planta Medica, 79 (7), 562–575. https://pubmed.ncbi.nlm.nih.gov/23136064/ Verkaik, S., Kamperman, A. M., van Westrhenen, R., & Schulte, P. F. J. (2019). Comparison of Vitex agnus-castus extracts with placebo in reducing menopausal symptoms: A systematic review and meta-analysis. Phytotherapy Research, 33 (11), 2815–2826. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887765/